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Friend Leukemia Virus Integration 1 (FLI1) is a critical transcription factor (TF) in terminal megakaryocyte
differentiation. It is amongst the genes missing from an inherited hemizygous deletion on chromosome
11q termed Jacobsen syndrome and often results in a dysmegakaryopoiesis and
macrothrombocytopenia termed Paris Trousseau syndrome (PTSx) described as being due to FLI1 allelic
exclusion. It has also been reported that heterozygote FLI1 mutations in its DNA-binding domain region
cause thrombocytopenia in patients suspected to have inherited platelet defects. To date, there are no
reports containing comprehensive in vitro or in vivo characterization of platelet defects due to
heterozygous FLI1 deletion or mutations, or that of platelets expressing increased levels of FLI1. We used
induced pluripotent stem cell (iPSC)- derived megakaryocytes (iMegs) to determine if the platelet disorder
observed in PTSx could be replicated, either with iPSCs generated from a PTSx patient or from a targeted
heterozygous knockout of FLI1 (FLI1+/-) in control iPSCs. These studies indicate that PTSx and FLI1+/iMegs replicate many of the clinical features described in PTSx and showed more in vitro injury to the
resulting iMegs with fewer platelets released in vivo. These platelets had shortened half-lives and were
functionally defective. We then examined whether increased levels of FLI1 would affect
megakaryopoiesis and thrombopoiesis, and found an increased number of iMegs with less in vitro injury
compared to control iMegs. FLI1-overexpressing iMegs also released more platelets in recipient mice
with increased half-life and functionality. These studies confirm FLI1 heterozygosity results in defects in
megakaryopoiesis and thrombopoiesis similar to that noted with other megakaryocyte-specific TFs, but
unlike those TFs, FLI1 overexpression is not associated with quality or quantitative platelet deficiencies,
but improved yield and functionality that may have clinical applicability.
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ABSTRACT
FLI1 EXPRESSION LEVELS DURING MEGAKARYOPOIESIS AFFECT THROMBOPOIESIS
AND PLATELET BIOLOGY
Karen K. Vo
Mortimer Poncz, M.D.
Friend Leukemia Virus Integration 1 (FLI1) is a critical transcription factor (TF) in terminal
megakaryocyte differentiation. It is amongst the genes missing from an inherited hemizygous
deletion

on

chromosome

11q

termed

Jacobsen

syndrome

and

often

results

in

a

dysmegakaryopoiesis and macrothrombocytopenia termed Paris Trousseau syndrome (PTSx)
described as being due to FLI1 allelic exclusion. It has also been reported that heterozygote FLI1
mutations in its DNA-binding domain region cause thrombocytopenia in patients suspected to
have inherited platelet defects. To date, there are no reports containing comprehensive in vitro or
in vivo characterization of platelet defects due to heterozygous FLI1 deletion or mutations, or that
of platelets expressing increased levels of FLI1. We used induced pluripotent stem cell (iPSC)derived megakaryocytes (iMegs) to determine if the platelet disorder observed in PTSx could be
replicated, either with iPSCs generated from a PTSx patient or from a targeted heterozygous
+/-

knockout of FLI1 (FLI1 ) in control iPSCs. These studies indicate that PTSx and FLI1

+/-

iMegs

replicate many of the clinical features described in PTSx and showed more in vitro injury to the
resulting iMegs with fewer platelets released in vivo. These platelets had shortened half-lives and
were functionally defective. We then examined whether increased levels of FLI1 would affect
megakaryopoiesis and thrombopoiesis, and found an increased number of iMegs with less in vitro
injury compared to control iMegs. FLI1-overexpressing iMegs also released more platelets in
recipient mice with increased half-life and functionality. These studies confirm FLI1 heterozygosity
results in defects in megakaryopoiesis and thrombopoiesis similar to that noted with other
megakaryocyte-specific TFs, but unlike those TFs, FLI1 overexpression is not associated with
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quality or quantitative platelet deficiencies, but improved yield and functionality that may have
clinical applicability.
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CHAPTER 1 – Introduction

1

Overview of hematopoiesis
Hematopoiesis is a complex process involving simultaneous regulation of
multiple genes by multiple cytokines and transcription factors (TF) to differentiate cells
successfully from a progenitor state to a mature blood cell. In the adult, the pluripotent
hematopoietic stem cells (HSC) reside primarily in the bone marrow1 and are
responsible throughout one’s extra-uterine lifetime for maintaining and replenishing all
blood cell lineages2: red, white and platelet. Additional discussion of hematopoiesis can
be found in the section entitled “Primitive versus definitive hematopoiesis.” Erythroid
cells are the biconcave discoid red blood cells that make up the bulk of total blood cells3.
These hemoglobin-laden red cells are responsible for delivering O2 to all tissues while at
the same time transporting CO2 away to be exchanged for O2 again in the lungs4. White
blood cells are the mainstays of the immune system5. Various white cell lineages provide
specific components of our immune response to our environment, including pathogens
like bacteria and viruses, either immediately via phagocytosis by macrophages6 and
leukocytes7 or via a more long-term strategy with cellular response by T cells5 and
antibody production by B cells8. Finally, platelets are small cell fragments released from
large megakaryocytes9. Platelets are highly organized with specific surface receptors
and granules containing clotting factors and many other bioactive molecules10. In
response to vascular injury, platelets become activated and release their granule
contents as they take part in hemostasis10. Overall, HSCs would not be able to
effectively and reliably undergo balanced differentiation into these specialized blood cell
types without proper and finely tuned positive and negative regulation.
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HSC differentiation via cytokine and TF regulation
The fate of the HSCs is determined by both extracellular cytokines and
intracellular TFs. Cytokines are small proteins that act as a ligand to their corresponding
extracellular receptors, that when bound, leads to intracellular signal transduction,
ending in transcriptional changes11. The cytokine erythropoietin (EPO) is responsible for
erythroid maturation, where binding of EPO to its receptor EPOR causes receptor
conformational changes followed by a signal transduction pathway involving Jak/STAT
family members that ultimately ends in upregulation of erythroid-specific genes12. For
myeloid cells and lymphocytes, the interleukin (IL) family of cytokines is the major driver
of differentiation from the pluripotent HSCs13. Similarly, thrombopoietin (TPO) binding to
its receptor Myeloproliferative Leukemia Protein (MPL) is the primary extracellular driver
of megakaryocyte maturation, also known as megakaryopoiesis13.
Downstream of these cytokines, TFs play a pivotal and direct role in activating
and inactivating lineage-specific genes. For example, GATA-binding Protein 1
(GATA1)14 determines the fate of the erythroid cells while NOTCH1 is responsible for T
cell

commitment15.

Specifically

focusing

on

transcriptional

regulation

of

megakaryopoiesis, there are several TFs that contribute to this unique hematopoietic
commitment pathway. Amongst these are also GATA116; its coactivator Friend of GATA1
(FOG1)17; Runt-Related Transcription Factor 1 (RUNX1)18,19; Nuclear Factor, Erythroid 2
(NFE2)19; ETS Proto-Oncogene 1, Transcription Factor (ETS1)20 and Friend Leukemia
Virus Integration 1 (FLI1)19,21. The importance and influence of the TF FLI1 on
megakaryopoiesis will be discussed in greater detail.
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Megakaryopoiesis is driven by transcriptional regulation
At the heart of HSC lineage commitment are TFs that drive expression or
repression of genes responsible for the eventual morphology and functions of a blood
cell. These intrinsic regulatory TFs are either expressed continuously or at specific
stages during the HSC differentiation process. HSCs reside at the apex of the blood cell
lineage commitment pathway and are classically described as first driven towards either
the common lymphoid progenitor (CLP) fate by the TFs IKAROS Family Zinc Finger 1
(IKZF1), Spi-1 Proto-Oncogene (SPI1) and GATA322 or to the common myeloid
progenitor (CMP) fate by simultaneous expression of SPI1 and GATA123. The CLPs
ultimately give rise to T cells, B cells and natural killer cells, whereas CMPs go on to
become granulocytes, monocytes and the bipotent megakaryocyte-erythroid progenitors
(MEP)23. Specifically for megakaryocytes, several key TFs expressed in a temporally
appropriate manner determine the commitment of MEPs away from the erythroid and to
the megakaryocytic lineage: GATA116, FOG117, RUNX118,19, NFE219 and a few members
of the ETS TF family19-21.
While GATA1 may be important for erythroid maturation, multiple studies have
also shown a role for GATA1 in megakaryopoiesis. Indirectly, its megakaryopoiesis
influence was shown via ectopic expression of Gata1, where avian myeloblasts could be
reprogramed to other blood lineages, including thrombocytes (the avian equivalent of
megakaryocytes)24. More concrete evidence was presented in a study where loss of
murine Gata1 in the megakaryocyte lineage severely impaired megakaryocyte
proliferation and maturation; thereby causing reduced platelet counts16. Moreover, a
mouse embryonic stem (ES) cell line lacking Gata1 had blocked early erythroid and
4

megakaryocyte maturation, but this phenotype was abrogated when Gata1 was
restored25. These studies suggest that GATA1 plays a role in early MEP cell
commitment from the CMPs.
The TF FOG1 is highly expressed in the megakaryocyte lineage26. This TF was
confirmed to be important for megakaryopoiesis when embryonic lethal Fog1-/- mice
were reported to have a complete absence of megakaryocyte colonies when yolk sac
and fetal liver cells were harvested and cultured in vitro27. It was also shown to complex
with GATA1 during erythroid and megakaryocytic differentiation26,28, suggesting an
influence on the differentiation of MEPs to erythrocytes and megakaryocytes.
Furthermore,

the

prevention

of

GATA1/FOG1

binding

led

to

defective

megakaryopoiesis29.
RUNX1 is another TF that physically cooperates with GATA1 to drive
transcription of megakaryocyte-specific genes18. Inducible deletion of Runx1 in mice
inhibited megakaryocyte maturation, resulting in the presence of small, immature
micromegakaryocytes in the bone marrow30. A study suggested RUNX1 may be an
important early stage TF for promoting megakaryocyte proliferation, showing that siRNAmediated suppression of RUNX1 in a megakaryoblastic leukemia cell line blocked
proliferation and decreased megakaryocyte maturation markers31.
NFE2, another TF originally discovered as important for erythroid differentiation,
exists as a heterodimer with a hematopoietic tissue specific p45 subunit and a
ubiquitous maf subunit32. It was later found to also be involved in megakaryopoiesis
when overexpression of the p45 subunit enhanced late stage megakaryopoiesis and
pro-platelet formation and release33. Additionally, mice that lack any NFE2 p45 had a
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mild red cell phenotype but were unable to produce any platelets resulting from a block
in late megakaryocyte maturation34.

The ETS TF family and megakaryopoiesis
The ETS family is among the largest group of TFs that are linked to a plethora of
functions, including but not limited to cellular differentiation and proliferation35. All
members of this TF family share a highly conserved DNA-binding domain – the ETS
domain – that recognizes an 11-base pair (bp) DNA sequence containing a purine-rich
5’-GGA-3’ central motif36,37. The 5’ and 3’ ends of this 11-bp region govern the DNAbinding specificity of each ETS member37. It has been suggested that ETS DNA-binding
could have two modes of action: a promiscuous binding for regulation of housekeeping
genes and a more specific binding for specialized genes38. In addition to their activity at
the ETS domain, this family of TFs has the ability to undergo protein-protein interactions
with other ETS family members and with other proteins for more enhanced and specific
transcriptional regulation of many proliferation and differentiation events, including
megakaryopoiesis35.
The founding member of this TF family, ETS139, has been shown to be
upregulated during megakaryocytic differentiation from cord blood40 and its expression
maintained throughout megakaryopoiesis20. Furthermore, when ETS1 is overexpressed
in erythroid cells, a maturation block coupled with decreased red cell-specific proteins
was observed. Conversely, overexpression of ETS1 in megakaryocytes increased cell
proliferation and upregulated megakaryocytic markers20. Interestingly, ETS1 and GATA1
can either independently or synergistically transactivate the promoter of the
6

megakaryocyte surface glycoprotein (GP) IIb, also known as αIIb, in HeLa cells41. The
GA Binding Protein Transcription Factor Alpha Subunit (GABPA) ETS TF controls
expression of early megakaryocyte genes like ITGA2B and MPL21. SPI1 is another
member of this family that is involved in megakaryopoiesis. Binding of GATA1 and SPI1
on a regulatory element of FLI1, another ETS TF, may function as transcription
regulation of this TF42. ERG and ETS2 are other ETS members involved in positive
regulation of megakaryocyte development43,44, whereas ETS variant 6 (ETV6) and
Erythroid

Kruppel-Like

megakaryopoiesis

via

Factor
inhibition

(EKLF)
of

were

FLI1

shown

activity

to

and

act

negatively

enhancing

on

erythroid

differentiation45,46.
Perhaps the best-characterized ETS TF family member involved in positive
stimulation of megakaryopoiesis is FLI1. This TF has been shown, in studies of cell lines
and mouse models, to be essential for MEP commitment to the megakaryocyte
lineage47,48 and is highly expressed during megakaryocyte maturation49. Overexpression
of FLI1 in the erythroleukemia cell line K562 was able to alter cell size, morphology and
gene expression to a megakaryocytic phenotype47. This same group later reported that
FLI1 could even block erythroid differentiation via the inhibition of GATA148, which is
crucial for the differentiation of MEPs25,50 as well as red cell maturation51. Mouse models
have also confirmed the role of FLI1 in megakaryopoiesis. Fli1-/- embryos die from brain
hemorrhages at E11.5 due in part to dysmegakaryopoiesis and in part from vasculature
defects. When the E11.5 fetal liver progenitors were evaluated in an in vitro colony
formation assay, this group found an increase in the number of micromegakaryocytes
with abnormal ultrastructures52. Another model with a milder disruption of mouse Fli1
expressing a truncated protein that lacks the C-terminal ETS DNA-binding domain
7

reported reduced viability with thrombocytopenia and platelet aggregation and activation
defects observed in the homozygous mice53. An inducible deletion of Fli1 in adult mice
resulted in increased numbers of MEPs as well as erythroid cells while exhibiting a
drastic decrease in mature megakaryocytes54. Overall, cell line and mouse model
studies of FLI1 suggest the indispensable role of this TF in not only MEP commitment to
the megakaryocyte lineage but also in late stage maturation of those megakaryocytes.

Platelet clinical disorders related to transcription factor defects
Because the above TFs have been experimentally proven to be crucial to the
megakaryocyte lineage, it is no surprise that deficiencies of those TFs can cause a
multitude of symptoms in patients related to defects in developing megakaryocytes, from
mild to moderate thrombocytopenia and severe platelet defects. Defects in TFs that lead
to a megakaryocyte or platelet phenotype are discussed below with an emphasis placed
on the defects due to disruptions in FLI1.

GATA1
Since GATA1 is required at very early stages of HSC differentiation25, it is
expected that genetic mutations of GATA1 would affect multiple blood lineages. Indeed,
GATA1 is implicated in deficiencies of the erythroid, myeloid as well as megakaryocyte
cells55. This TF is located on the X chromosome and is associated with several X-linked
disorders in which females are asymptomatic or present with milder symptoms than
seen in males where mild to severe macrothrombocytopenia and/or anemia and
8

neutropenia are reported55. An inherited V205M mutation in GATA1 that disrupts its
binding to FOG1 but leaves the DNA-binding region intact was reported to cause
macrothrombocytopenia and dyserythropoietic anemia56. The following similar clinical
mutations affecting GATA1 interaction with FOG1, but not to DNA, have since been
discovered: G208S57, G208R58 and D218G59 causing macrothrombocytopenia and
dyserythropoiesis but not always resulting in anemia; and D218Y60 causing severe
macrothrombocytopenia and anemia with early mortality. These mutations suggest that
the FOG1 cofactor is essential in normal megakaryopoiesis and, to a lesser extent,
erythropoiesis.
Mutations in GATA1 that affect its DNA-binding capability can also cause a
megakaryocyte defect. The R216Q61,62 mutation causes thrombocytopenia and βthalassemia while R216W63, a different substitution at the same amino acid residue,
results in the additional manifestation of congenital erythropoietic porphyria63. Splice
mutations that result in loss of full-length GATA1 and resulting in expression of only a
naturally-occurring, shortened version of GATA1 (termed GATA1short or GATA1s)
lacking the N-terminal transcription activation domain can severely hinder erythropoiesis
and cause megakaryocyte and platelet defects55. This GATA1s isoform also affects
production of white cells and neutrophils55. Overall, patients harboring mutations in
GATA1 that reduces its activity either through loss of binding to its cofactor FOG1, direct
binding to DNA targets, or loss of the full-length isoform presents with not only
dyserythropoiesis but also macrothrombocytopenia often associated with concurrent
platelet functional defect.
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RUNX1
Familial

platelet

disorder

(FPD)

in

a

family

with

a

presentation

of

thrombocytopenia, platelet aggregation defects and a high propensity to develop acute
myelogenous leukemia (AML) was linked to a locus on chromosome 21q22.1-22.2
where RUNX1 resides64. Haploinsufficiency of RUNX1, either by nonsense mutations or
intragenic deletion of one allele, was later confirmed to be responsible for FPD/AML65.
Additionally, various mutations that abrogated the DNA-binding capacity of RUNX1 were
found in other families with FPD/AML66. In other FPD/AML mutations, the ability of
RUNX1 to heterodimerize with binding partner Core Binding Factor β, known to stabilize
the interaction of the complex with DNA67,68 and to protect it from proteolytic
degradation69, was lost66. Because several possible binding sites for RUNX1 were found
in the promoter region of MPL, decreased MPL surface expression at normal TPO levels
is thought to be the mechanism for thrombocytopenia in the p.Thr219Argfs* RUNX1
defect70. This mechanism was further elucidated when the mutated RUNX1 was shown
to be unable to regulate NFE2 expression, thereby influencing platelet granule and
surface protein expression71. Many platelet genes, including Platelet Factor 4 (PF4,
CXCL4)72 and platelet protein kinase C-θ73, have since been reported to also be
regulated by RUNX1.

FLI1
The FLI1 gene is found on chromosome 11q22.3-2474 and is one of many genes
hemizygously lost due to chromosome 11q terminal deletions of varying sizes75,76,
resulting in Jacobsen syndrome (JSx). Many of these deletions arise de novo, with an
10

estimated 1 in 100,000 prevalence77. Because these deletions can sometimes be up to
20 Mbp in length, patients with JSx can present with a multitude of defects, including
cardiac and kidney defects, cognitive impairments, psychomotor retardation, facial
dysmorphism, and macrothrombocytopenia76. While not all patients have the same set of
symptoms, over 90% have a bleeding diathesis called Paris Trousseau syndrome
(PTSx)78,79. PTSx patients have an increase in immature micromegakaryocytes in their
bone marrow and macrothrombocytopenia with 10-15% of their platelets containing
fused giant α-granules and secretion defects. The perinatal thrombocytopenia can
lessen with age, but platelet function may not, suggesting that the platelet defect persists
even if the platelet numbers return to usually the low normal range79. Because ETS1 and
FLI1 are both deleted in PTSx (Figure 1.1) and are physically only separated by ~170
kb80, it has been suggested that the combinatorial hemizygous loss of these two genes
is to blame for the PTSx macrothrombocytopenia81. However, mice that are
heterozygous for both genes only have a 19% reduction in platelet count with no
abnormal platelet morphology and show no megakaryocyte defects81. A study done on
peripheral blood CD34+ cells harvested from 2 PTSx patients concluded that
hemizygous loss of FLI1 is responsible for the thrombocytopenia after lentivirusmediated overexpression of FLI1 in these cells restored normal megakaryopoiesis82.
Unfortunately, this study failed to recognize the possibility that FLI1 overexpression by
itself can drive progenitor cells to differentiate into the megakaryocyte lineage47,48,
thereby not necessarily correcting the dysmegakaryopoiesis but rather just tipping the
scale away from erythroid or myeloid differentiation and towards megakaryocytic
differentiation. Moreover, this paper claimed that FLI1 expression was controlled by
allelic exclusion where half of progenitor cells would be expressing normal levels of FLI1
11

and the other half with zero expression. This idea that FLI1 undergoes allelic exclusion
remains in the literature82,83 in spite of the observation that no one has shown two
distinct platelet populations with one defective qualitatively and quantitatively and the
other normal.
Two recent reports have suggested that the large chromosomal deletions found
in JSx are not needed for PTSx-like platelet defects. A next generation sequencing study
of 13 unrelated families with excessive bleeding and suspected inherited platelet
disorder found 3 cases of different heterozygous FLI1 mutations84. There were 2
substitution mutations at R337W and Y343C and a 4-bp deletion at p.Asn331Thrfs*4. All
3 mutations were located in the ETS DNA-binding domain. FLI1 was reported for the first
time to have an autosomal recessive inheritance pattern when a family was found to
have PTSx-like macrothrombocytopenia and platelet secretion defects only in the
homozygous offspring but not heterozygous parents85. This family’s R324W mutation is
also located in the ETS DNA-binding domain of FLI1. No other hematological
abnormalities were observed in the patients harboring FLI1 mutations. Overall, the
higher than expected prevalence of FLI1 mutations in patients with undiagnosed platelet
disorders would suggest this TF is responsible for more cases of inherited platelet
disorders than previously thought.

Challenges to studying megakaryopoiesis associated with FLI1
Surprisingly, the current literature on the influence of FLI1 on human
megakaryopoiesis and the details of the thrombocytopenia and platelet functional
12

defects observed in PTSx hemizygous deletions and the newly described heterozygous
mutations are underdeveloped. While there is a recent study showing FLI1 to account for
a larger than previously thought portion of inherited platelet disorder84, there are still
many challenges to clinical studies of this TF. PTSx patients with FLI1 deletions or
mutations are rare, with many dying in infancy86. Given the variable genotypic
background of these rare PTSx individuals and those with inherited FLI1 mutations,
linking specific details of the phenotype to the FLI1 gene can be challenging.
Comprehensive in vitro studies can be done on immortalized cell lines, but these studies
may not recapitulate patient phenotype. In vivo mouse models do not fully replicate the
biology of this TF in humans in that the Fli1+/- mice do not have thrombocytopenia. Thus,
a solution that addresses these challenges could allow for detailed analysis of the effects
of FLI1 deficiency on megakaryopoiesis, thrombopoiesis and platelet biology not yet
addressed. Furthermore, the question of allelic exclusion of FLI1 and the influence of
optimal FLI1 levels in these processes could also be studied.

PTSx patient clinical data and primary cells
Studies using patient clinical data and primary cells can be very limited if the
patient pool is small, with many of the patients facing more pressing challenges like lifethreatening organ defects. For JSx and PTSx, there are only about 200 reports of
confirmed chromosome 11qter deletions. While clinical data like platelet counts and
platelet aggregation defects serve to confirm the PTSx macrothrombocytopenia
phenotype, more work still needs to be done at the molecular level to study and
deconstruct the disease mechanism. Most reports of PTSx patients contain clinical
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analysis, but not all of them contain molecular analysis, like gene expression profiling, of
megakaryocytes and platelets. The disease itself manifests as a problem, since it is hard
to justify extracting bone marrow or enough whole blood on which to perform detailed in
vitro studies when the patient has a bleeding diathesis. To date, there has been one
mechanistic study on PTSx that used primary CD34+ cells extracted from patients82.
Even so, this group was only able to show limited in vitro data on 2 patients. Additionally,
no detailed megakaryocyte or platelet biology studies have been reported on the 3
heterozygous84 and one homozygous85 FLI1 mutations that have been recently
described.

Immortalized cell lines
Cell lines can provide researchers with an unlimited quantity of material to study.
Indeed, immortalized cell lines have been used to study the biology of FLI1 in
megakaryopoiesis, though this approach also has its limitations. For example, the
myelogenous leukemia cell line K562 was transduced with a retroviral construct to
overexpress FLI1, which created cells that were large, like megakaryocytes, and also
expressed the megakaryocyte-specific αIIb47. While this study was able to identify the
ability of retroviral FLI1 overexpression to cause a leukemia cell line to differentiate
along the megakaryocyte lineage, there were not studies that demonstrate that these
cells can undergo thrombopoiesis and release functional platelets. Immortalized cell
lines may also have a different phenotype than their origin tissue sources would suggest,
having gone through significant mutations during the immortalization process87.
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Mouse/animal models
For almost any human disease that has been studied, at least one animal model
has been created to evaluate the pathology at an organismal level. Most of these animal
models are created using mice due to their size, ease of breeding and cost.
Unfortunately in the case of FLI1, multiple mouse models proved that mice are not men.
In humans, haploinsufficiency of FLI1 results in the megakaryocyte and platelet defects
described above. In mice, however, only the homozygotes had a defective phenotype,
and heterozygotes display normal platelet counts and function52-54. One study even
reported a normal megakaryocyte/platelet phenotype in mice homozygous for a severely
mutated Fli1 expressing only its first 10 amino acids88. Of course, these mouse models
provide important insights into the in vivo biology of FLI1 on megakaryocyte
development, yet the incongruent inheritance pattern raises the question of how far we
can translate mouse studies to the clinical setting. No other species have been used to
create a FLI1-deficient model to study megakaryopoiesis.

Induced pluripotent stem cells and their applications in hematopoietic studies
To pursue additional insights into the role of FLI1 and its level in
megakaryopoiesis, thrombopoiesis and platelet biology in patients, we turn to an
alternative model using induced pluripotent stem cells (iPSC) for analysis. iPSCs are cell
lines that have been created by transducing somatic cells with a set of stem-cell specific
TFs, thereby reverting them back to a pluripotent state. This methodology was first
described in 2006 by Takahashi and Yamanaka, detailing the successful reprogramming
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of adult mouse fibroblasts to iPSCs after viral transduction of the TFs Oct3/4, Sox2, cMyc and Klf489. This group later showed the same could be done for human fibroblasts90.
These iPSCs proved to have ES cell morphology and gene expression profile.
Furthermore, when injected subcutaneously into mice, the tumors that develop exhibits
all three germ layers: endoderm, mesoderm and ectoderm89,90. Due to their ES-like
qualities, iPSCs have a wide variety of applications, especially in disease modeling.
The pluripotency of iPSCs proved very useful for researchers studying diseases
that are found in any tissue. It is now possible to collect a small sample of cells using
noninvasive procedures like a blood draw or skin biopsy from patients to create diseasespecific cell lines. iPSC lines have since been created from cells of patients with type 1
diabetes91, spinal muscular atrophy92, thalassemia and sickle cell anemia93 and many
other diseases. These iPSC lines can then be differentiated into the relevant tissues to
study specific disease pathology.
iPSCs are also self-renewing cell lines, meaning they can be cultured indefinitely.
This unique property provides a virtually unlimited amount of material with which studies
can be done. No longer do researchers studying rare diseases need to worry about
procuring a vast quantity of primary cells from patients. Even at smaller or remote
institutions where there may not necessarily be opportunities to obtain patient samples
to create iPSCs, numerous commercial and institutional cell banks have been set up
around the country and the world where one could send for very specific iPSC lines. The
pluripotent and self-renewing properties of iPSCs can provide an unparalleled access to
disease models not available otherwise.
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Disease modeling of hematopoietic disorders using iPSCs
In vitro modeling of hematological diseases using iPSCs has been welldocumented94,95. These lines, generated from patient fibroblasts or various blood cells,
retain the original genomic aberrations and could recapitulate the disease pathology
once differentiated in vitro. It is even possible to correct the genetic defect, as shown in
Fanconi anemia96, before iPSCs were generated and obtain disease-free hematopoietic
progenitor cells (HPC) that are more lineage-committed than the HSCs97.

Primitive versus definitive hematopoiesis
While iPSC technology is undeniably useful in studying the pathogenesis of
diseases, they do have limitations. This is especially concerning for hematopoietic
studies, where differentiation of iPSCs to the various blood cells may undergo either or
both primitive and definitive hematopoiesis. During mammalian hematopoiesis, different
blood progenitor cells are produced based on both spatial and temporal factors. The first
blood cells emerge in the yolk sac before circulation begins and then migrate to the
aorta-gonad-mesophrenos region as organs start to develop98. Later in fetal maturation,
hematopoiesis occurs mainly in the liver. The final region where hematopoiesis occurs,
shortly before birth and into adulthood, is the bone marrow98.
The first blood cells that arise from the yolk sac are primitive erythrocytes,
megakaryocytes and macrophages99. This first wave of hematopoietic progenitors
includes primitive or embryonic erythroid lineage100. These progenitor cells become large
nucleated erythroid cells expressing fetal e and z globin genes, which are then switched
to g globin in the fetal liver and b globin in the bone marrow for definitive
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erythrocytes101,102. The primitive megakaryocytes and macrophages, however, are
virtually indistinguishable from their definitive equivalents103. This presents a challenge in
identifying and characterizing primitive versus definitive megakaryocytes for in vitro
differentiation protocols where there are no spatial or temporal queues to establish their
status. Ideally, in vitro differentiation of ES cells and iPSCs to definitive multilineage
progenitors that have the ability to become other myeloid cells would allow for clinical
applications such as bone marrow transplantation.
The differentiation of iPSCs into HPCs was adapted and developed from the
already established ES differentiation protocol104. Like ES cell differentiation, the in vitro
iPSC differentiation program directs cells along the primitive streak105,106. This primitive
HPC differentiation is a challenge for translating this research into clinical use.
Regarding this issue, strides have been made with the overexpression of various
single107 or combinatorial TFs108 that favor definitive differentiation. The area of research
for directed iPSC differentiation towards definitive hematopoiesis is ongoing. Meanwhile,
the currently established protocol allows for comprehensive disease modeling and
mechanistic studies of hematopoietic disorders with the limitations of these iPSC lines
taken into account.

Summary
While

FLI1

has

been

established

as

an

important

TF

regulator

of

megakaryopoiesis, either through cell line or mouse model analyses, key questions in
studying FLI1-associated megakaryocyte and platelet defects as it pertains to human
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biology remains. I approach these questions using human iPSCs that express varying
levels of FLI1 during megakaryopoiesis, with iPSCs from a normal control line that has
then been gene-edited to establish isogenic sublines that were either FLI1 heterozygous
or that overexpressed FLI1. I also studied megakaryopoiesis with iPSCs established
from a patient with PTSx which we gene edited to overexpress FLI1. I hypothesize that
the expression level of FLI1 during megakaryopoiesis has a direct, correlative influence
on megakaryocyte maturation, subsequent thrombopoiesis and in vivo-released platelet
quality. The scope of this thesis encompasses the creation of relevant iPSCs to study
FLI1-associated

megakaryopoiesis

as

well

as

detailed

in

vitro

and

in

vivo

characterization of megakaryocytes and platelets. Chapter 2 outlines the generation of
iPSCs and their genome editing to effectively study FLI1 influence on megakaryopoiesis
and thrombopoiesis. Chapter 3 details the in vitro effects of FLI1 on megakaryocytes and
platelets. In vivo analyses of thrombopoiesis and released platelet quality are described
in Chapter 4. Finally, in Chapter 5, I will discuss the relevant findings and potential
clinical implications from these studies.
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Figure 1.1. Schematic of 4 PTSx 11qter deletions.
Schematic illustrating 4 PTSx 11qter chromosomal deletions of various sizes, all
containing FLI1 and ETS1109. The PTSx patient studied in this thesis is visualized by the
blue box. Deletion was determined by chromosomal microarray by CHOP’s Genomic
Diagnostics Laboratory (Philadelphia, PA).
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CHAPTER 2 – Creation of FLI1-iPSC lines using gene-editing strategies
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Abstract
I describe in this Chapter the generation of human iPSCs from a normal control
wildtype (WT) and a PTSx patient, the use of zinc-finger nuclease (ZFN) technology to
transgenically express FLI1 in tissues of interest and the use of transcription activator
like effector nuclease (TALEN) to mutate FLI1 on these iPSC lines. First, using a ZFNmediated protocol previously developed by our group, I generated megakaryocytespecific FLI1-overexpressed control (WT-OE) and PTSx (PTSx-OE) iPSCs. The WT line
was used to create a heterozygous FLI1+/- iPSC line with the TALEN gene targeting
methodology. ZFN, TALEN, and more recently, clustered regularly interspaced short
palindromic repeats (CRISPR)/CRISPR-associated protein (Cas)9 technologies are
relatively novel technologies that have facilitated sequence-specific mutagenesis. The
experimental protocols for these powerful new tools are relatively easy to learn and carry
out, allowing for fast and efficient in vitro-generation of gene-edited cell lines or primary
cells and makes possible in vivo gene editing when used in combination with novel in
vivo-nanoparticle delivery methods. Coupled with iPSC technology, gene editing allows
for normal control lines to be mutated to recapitulate patient-specific phenotypes and
patient lines can be returned to normal via the insertion of either a missing or corrected
DNA sequence. Other cell line generation techniques used during the course of this
thesis are also described in this Chapter.
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Introduction
The study of rare disorders that do not have a suitable cell line or animal model
that can faithfully reiterate the human phenotype can be a challenging undertaking.
However, with the successful reprogramming of somatic cells into pluripotent stem cells
of mice in 200689 and humans in 200790, many of these challenges have since been
addressed. With this technology, a pluripotent and self-renewing iPSC line could be
made directly from a small sample of blood or skin tissue of relevant patients and
controls. The pluripotency property gives researchers the flexibility of studying diseases
affecting one or multiple tissue types by differentiating these cell lines into those specific
tissues. The self-renewing capability of these iPSCs allows for a virtually unlimited
source of material for experimentation. Moreover, since these are cell lines, further
manipulation employing the use of targeted introduction of transgenes and gene-editing
techniques enables generation of properly controlled lines, including a normal control
(WT) line and lines with a specific mutation that can be theoretically studied on the same
genotype background.
The pluripotency capability of iPSCs generated from humans, mice or other
organisms has been capitalized on for various studies. Directed in vitro differentiation of
these cells into multiple tissues; including neuronal, cardiac and hematopoietic cells; has
been reported110,111. One of the first reports of an iPSC line generated for disease
modeling was for spinal muscular dystrophy, where motor neurons differentiated from
those iPSCs exhibited degeneration characteristics seen in the patients’ neurons92.
Similarly, cardiomyocytes differentiated from iPSCs generated from patients with long
QT syndrome had the same typical cardiac phenotypes associated with the disease112.
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Early iPSC models of hematological disorders include Fanconi anemia96, thalassemia93,
sickle cell anemia93 and myeoloproliferative disorders113. Platelet disorders that have
been successfully modeled and corrected in the iPSC system include congenital
amegakaryocytic thrombocytopenia114 and Glanzmann thrombasthenia115.
Another advantage of using iPSCs to model diseases is the ability to modify the
genome of these cell lines for further and more thorough examination of patient-specific
genetic pathogenesis. Our laboratory has previously reported megakaryocyte lineagespecific expression of transgenes using ZFNs at the adeno-associated virus integration
1 (AAVS1) locus115. More recently, advances in alternative technologies such as
TALENs and CRISPR/Cas9 have allowed for faster development of gene-editing
strategies for in vitro as well as in vivo applications. The basic principle behind these
three technologies is similar: there is a sequence-specific DNA-recognition portion along
with a catalytic portion for DNA cleavage that takes advantage of the endogenous DNA
repair mechanism to effect genomic changes.
ZFNs contain a modular portion that has been designed to bind to a specific DNA
sequence called a zinc finger domain and is bound to a catalytic restriction
endonuclease domain. In 1996, the first report of the fusion of the modular zinc finger
domain to the cleavage domain of type IIS endonuclease FokI characterized the DNA
cutting patterns of this fusion protein116. Each modular zinc finger motif binds a 2- to 4-bp
DNA sequence, with a typical ZFN containing a sequence of 3 to 6 different zinc finger
modules to confer up to an 18-bp sequence-specific binding117,118. Because the FokI
endonuclease activity requires dimerization119, a pair of ZFNs binding to opposite sides
on the DNA target site is required for double-strand breaks, which increases the
specificity of the ZFN. Gene correction using ZFNs was first demonstrated in 2003,
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where a green fluorescent protein (GFP) mutation was successfully corrected120. Clinical
applications of ZFNs are being developed for HIV resistance in T cells121,122. While the
basic and translational benefits of ZFNs have been established, their modular DNAbinding motifs have limitations. Specificity can be limited as the zinc finger modules can
sometimes only recognize 2 of 3 bases, thereby increasing the chances of off-target
recognition123,124.
A more recent discovery in the sequence-specific targeting of DNA is TALEN
technology. Similar to ZFNs, TALENs are fusion proteins consisting of a sequenceprogrammable TALE DNA-binding domain and the same FokI endonuclease used in
ZFNs. The TALE portion is derived from bacteria125 and each domain contains a
conserved 33-35 amino acid repeat with repeat variable diresidues (RVD) at positions 12
and 13 conferring nucleotide specificity126. TALEs could then be designed to bind with
high affinity to specific DNA sequences by using different RVDs that correspond to the
four nucleotides adenine, guanine, thymine and cytosine127. Another advantage other
than high specificity is that TALEN construction is much simpler than ZFN
construction128, with high-throughput TALEN assembly129 aiding in the creation of a
library spanning the human genome130. Like ZFNs, however, complicated and limited
construct design as well as relatively limited efficacy and partial off-target concerns131
need to be addressed with the use of TALENs in gene editing.
Lastly, the development of CRISPR/Cas9 for specific DNA targeting in the past
few years has provided an even more simplified protocol for gene editing. CRISPR were
discovered to be used by bacteria and archaea in conjunction with the Cas
endonuclease as an adaptive immunity response to destroy foreign DNA132,133. The most
commonly used system for eukaryotic genome targeting is the Type II CRISPR
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containing the Cas9 endonuclease and the guide RNA (gRNA) consisting of the CRISPR
RNA (crRNA) that confers sequence specificity and the transactivating crRNA
(tracrRNA) that complexes with the Cas134. When all components of the CRISPR/Cas9
are delivered to the cell, the gRNA directs the Cas9 to the target sequence and DNA
cleavage occurs three base pairs upstream of the NGG protospacer-associated motif
(PAM) on the target DNA strand135. Variants of the Cas9 endonuclease have since been
discovered that can provide higher efficiency or specificity of this system136.
The goal of all three described technologies is to induce double-strand DNA
breaks at very specific, targeted sites in the genome then taking advantage of cell’s own
DNA repair mechanisms to create site-specific mutagenesis. The DNA breaks can be
repaired either through the homology-directed repair (HDR) or the error-prone nonhomologous end joining (NHEJ) pathways137. In the HDR pathway, the cellular DNA
repair relies on a template to introduce single nucleotides or transgenes at the DNA
break138. The NHEJ repair mechanism detects a double-strand break and simply ligates
the ends back together. Because this method does not use a template for repair, it often
causes the introduction, at the repair site, of small insertions or deletions that can cause
a single amino acid or a frameshift mutation139. These two endogenous DNA repair
mechanisms facilitate the efficiency of gene-editing tools described.
This Chapter provides detailed descriptions of the generation of iPSCs from a
control wildtype (WT) and a PTSx patient with subsequent gene editing techniques used
on these lines. Overexpression of FLI1 was performed using the ZFN technique on WT
(WT-OE) and PTSx (PTSx-OE) lines. A FLI1+/- line (FLI1+/-) was created using the
TALEN method. I will also describe the CRISPR/Cas9 gRNAs generated in the attempt
to create FLI1-/- and ETS1-/- iPSCs.
26

Methods
Plasmids used for reprogramming and gene editing
The WT iPSC line was generated as described previously140. Co-transfection of a
tetracycline-inducible

expression

cassette

pHAGE-Tet-hSTEMCCA

(Figure

2.1A)

containing the four reprogramming factors OCT4, SOX2, KLF4 and MYC and the
reverse tetracycline transactivator protein (rTTA) containing vector pHAGE2-CMV-rTTA
resulted in cell reprogramming in the presence of doxycycline.
The PTSx iPSC line was generated using a humanized, floxed single excisable
lentiviral stem cell cassette hSTEMCCA-loxP (Figure 2.2A) described previously141. This
polycistronic vector contains the four reprogramming factors OCT4, SOX2, KLF4 and
MYC. The resulting integration of this floxed vector can be excised on exposure to Cre
recombinase with the transient transfection of pHAGE2-Cre-IRES-PuroR (Figure 2.2B).
The megakaryocyte-specific transgene expression strategy was previously
described115. Two ZFN plasmids under the constitutively active phosphoglycerate kinase
(PGK) promoter and targeting the AAVS1 locus were used: pPGK-AAVS1-ZFNL and
pPGK-AAVS1-ZFNR (Figures 2.3A and 2.3B). A third plasmid carrying the donor FLI1
cDNA, AAVS1-Gp1ba-hFLI1 (Figures 2.3C and 2.4), contains a murine megakaryocytespecific Gp1ba promoter.

Generation of the WT iPSC line
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The WT iPSC used for this thesis was generated by the Children’s Hospital of
Philadelphia (CHOP) Human Pluripotent Stem Cell Core (Philadelphia, PA) and named
WTBM1-8115. Bone marrow cells were purchased from the Stem Cell Core at the
University of Pennsylvania (Philadelphia, PA) and approximately 1 X 105 CD34+ cells
were selected and seeded in 35-mm culture plates. Cells were co-transfected in the
presence of 5 μg/ml polybrene with lentiviral vectors pHAGE-Tet-hSTEMCCA and
pHAGE2-CMV-rTTA (Figure 2.1)140. The medium was replaced after 16 hours with iPSC
medium consisting of DMEM/F12 (Gibco, Carlsbad, CA) with 20% KnockOut Serum
Replacement (Invitrogen, Carlsbad, CA), 1 mM L-glutamine (Sigma-Aldrich, St. Louis,
MO), 0.1 mM β-mercaptoethanol (Sigma-Aldrich), 1% nonessential amino acid solution
(Invitrogen), and 10 ng/ml basic fibroblast growth factor (bFGF) (R&D Systems,
Minneapolis, MN). Doxycycline at 1 μg/ml was supplemented in the iPSC medium from
the first day of reprogramming and removed 2-3 weeks later after individual iPSC clones
resistant to doxycycline were mechanically picked with a 10 μl pipette tip under 40X
magnification. These clones were selected based on iPSC morphology and colony size
spanning at least half of the magnification field (Figure 2.5).

Generation of the PTSx iPSC line
The PTSx iPSC line was generated by the CHOP Human Pluripotent Stem Cell
Core with fibroblasts collected from a PTSx patient (Table 2.1 and Figure 1.1), using
reprogramming methodology as described141. Fibroblast cells were obtained as leftover
samples from the Division of Genomic Diagnostics Lab (CHOP), cultured in T75 plates
and split 1:3 when 80% confluent. Reprogramming was done after 3 passages, at which
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time approximately 1 X 105 fibroblasts were plated in DMEM with 10% FBS on a 0.01%
gelatin (Sigma-Aldrich)-coated 35-mm plastic tissue culture dish. The next day polybrene
was added to the media (5 μg/ml), and the cells were infected with the excisable
hSTEMCCA-loxP (Figure 2.2A) single cassette lentivirus. On day 2, the medium was
changed to iPSC medium. On day 6, the culture dish was trypsinized and passaged at a
1:16 split ratio onto two 0.01% gelatin-coated 10-cm culture dishes that had been plated
the day before with a feeder layer of irradiated mouse embryonic fibroblasts (irMEFs).
iPSC clones were picked as described above for WT iPSCs. The excision of viral
sequences was performed using the Hela Monster transfection reagent (Mirus, Madison,
WI) according to manufacturer’s instructions. A 35-mm tissue culture well of iPSC
colonies at 30% confluency and growing on puromycin-resistant MEFs (GlobalStem,
Gaithersburg, MD) were transiently transfected with medium containing 2 μg of
pHAGE2-Cre-IRES-PuroR (Figure 2.2B) plasmid DNA along with 6 μl of transfection
reagent and 3 μl of the Monster reagent. The medium was changed the next day with
iPSC supplemented with 1.2 μg/ml puromycin for selection 24 hours post transfection
and lasted for 48 hours. The re-emergence of iPSC colonies was noted within 1 week,
and colonies from each well were picked, as above, approximately 1-2 weeks later.

Pluripotency characterization of WT and PTSx iPSC lines
Analysis of pluripotency surface markers stage-specific embryonic antigen
(SSEA) 3, SSEA4, Tumor-related Antigen (TRA)-1-60 and TRA-1-81 was performed via
flow cytometry (Figure 2.6A). iPSCs were detached using Accutase (Invitrogen), washed
once in fluorescence-activated cell sorting (FACS) buffer of phosphate buffered saline
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(PBS, calcium chloride and magnesium chloride free, Gibco) containing 0.01% bovine
serum albumin (BSA, Sigma-Aldrich). Single cell suspensions at approximately 1-2 X 105
cells were stained in 100 μl FACS buffer. Antibodies were used (Table 2.2) at the
following dilutions: SSEA3 Alexa Fluor (AF) 488 1:200, SSEA4 AF 647 1:400, TRA-1-60
AF 488 1:50 and TRA-1-81 AF 647 1:50 (Biolegend, San Diego, CA). Cells were
incubated at room temperature (RT) for 15 minutes then washed once with FACS buffer
and resuspended in 200 μl of FACS buffer before data were collected using a BD
FACSCanto II (BD Biosciences, San Jose, CA) and analyzed using FlowJo software
(Tree Star, Ashland, OR).
For teratoma formation, approximately 6 X 106 iPSCs were harvested using
Accutase and resuspended in 140 μl of DMEM/F12. Immediately prior to injection, 60 μl
of Matrigel (BD Biosciences) was added to the cell suspension at 4°C, and the resulting
mixture injected subdermally between the scapulae of each anesthetized severe
combined

immunodeficiency

(SCID)-Beige

mouse

(strain

250,

Charles

River,

Wilmington, MA). Resulting tumors were harvested at 6-8 weeks post injection, fixed in
4% paraformaldehyde, and paraffin tissue sections were prepared and stained with
hematoxylin and eosin according to standard methods142 (Figure 2.6B). Karyotyping was
performed by Cell Line Genetics (Madison, WI) (Figure 2.6C).

Maintainence of iPSC lines
Maintenance of iPSCs is as previously described143. Reprogrammed cells were
cultured in iPSC medium. Culture dishes were coated with 0.01% sterile gelatin
(Millipore) before plating a feeder layer of irMEFs and were incubated at 37°C at 5% CO2
30

1-2 days prior to iPSC culturing. Passaging was performed approximately every 3-4
days at a 1:6 to 1:24 split ratio. Cells were incubated with Accutase for 3-5 minutes at
37°C to detach them from the dish, and then centrifuged at 1200 rpm for 3 minutes
before passaging at the appropriate split ratios in iPSC medium containing 10 μM Y27632 dihydrochloride Rho Kinase (ROCK) inhibitor (Tocris, Bristol, UK) overnight. iPSC
medium without ROCK inhibitor was changed every day except on Sundays, when cells
were fed with double the medium volume the previous day. The iPSCs were maintained
at 37°C at 5% O2 in the undifferentiated state for 20-30 passages before tossing and
thawing out of a fresh vial of cells.

Generation of WT-OE and PTSx-OE iPSC lines
Overexpression of FLI1 was performed by targeting the AAVS1 safe-harbor locus
using a Gp1ba-driven FLI1 transgene using ZFNs, as previously described for
expression of ITGA2B115 (Figure 2.3). WT and PTSx iPSCs were plated 24-48 hours
prior to transfection on 1:3 matrigel basement membrane matrix (Corning, Corning, NY)coated 35 mm dishes pre-seeded with drug-resistant MEFs. When cells were
approximately 30% confluent, they were washed 2X with Iscove's Modified Dulbecco's
Medium (IMDM, Gibco) and fed 2 ml of iPSC medium (20 ng/ml bFGF) 3 hours prior to
transfection. Cells were transiently co-transfected with 0.2 μg of each of the AAVS1targeting ZFN plasmids (pPGK-AAVS1-ZFNL and pPGK-AAVS1-ZFNR), 0.6 μg of a
vector containing the Gp1ba promoter construct driving the primary FLI1 transcript cDNA
(AAVS1-Gp1ba-hFLI1) and 3 μl of Roche x-tremeGENE9 in 100 μl IMDM mixture added
to 2 ml cell medium. The cells were washed once with IMDM the next day. iPSC medium
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supplemented with 0.5 μg/ml puromycin was changed for selection 48 hours post
transfection and lasted for 72 hours. The re-emergence of iPSC colonies was noted
within 1 week, and colonies were picked, as above, approximately 1-2 weeks later.

Generation of the FLI1+/- iPSC line
The heterozygous disruption of FLI1 was achieved by using TALEN nucleases
with

recognition-site

sequences

TCCCACCACAGCAGGAGT

and

TCCCAGTTGCAGTTCGCCCT within exon 2 (Figure 2.7). This pair of TALENs was
designed with the help of the University of Pennsylvania Gene Targeting Core
(Philadelphia, PA). WT iPSCs cells plated 24-48 hours prior to transfection on 1:3
matrigel-coated 35 mm dishes pre-seeded with drug-resistant MEFs. When cells were
approximately 30% confluent, they were washed 2X with Iscove's Modified Dulbecco's
Medium (IMDM) and fed 2 ml of iPSC medium with 20 ng/ml bFGF 3 hours prior to
transfection. Cells were co-transfected with 0.2 μg each of the two AAVS1-targeting ZFN
plasmids (pPGK-AAVS1-ZFNL and pPGK-AAVS1-ZFNR), 0.6 μg of a plasmid with
homology arms to the AAVS1 locus containing only the puromycin resistance gene
(AAVS1-SA-2A-puro-pA donor), 0.2 μg each of the two TALEN plasmids targeting FLI1
at exon 2 (TALEN-E2-L and TALEN-E2-R, Figure 2.7) and 3 μl of Roche x-tremeGENE9
in 100 μl IMDM mixture added to 2 ml cell medium. The cells were washed once with
IMDM the next day. iPSC medium supplemented with 0.5 μg/ml puromycin was changed
for selection 48 hours post transfection and lasted for 72 hours. The re-emergence of
iPSC colonies was noted within 1 week, and colonies were picked, as above,
approximately 1-2 weeks later.
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Confirmation of FLI1-modified iPSC lines
WT and PTSx iPSC clones targeted for FLI1 overexpression were confirmed to
contain either 1 or 2 copies of the transgene via Southern Blot analysis142,144 (Figure
2.8). Cells were passaged 3-4 times, then genomic DNA (gDNA) was purified using the
DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). 10-15 μg DNA was digested
with 2000 U of SphI-HF (New England Biolabs, Ipswich, MA) endonuclease overnight at
37°C then electrophoresed on a 0.7 % agarose gel with 0.1 mg/ml ethidium bromide
(Invitrogen) in Tris base, acetic acid and EDTA (TAE) buffer. The gel was depurinated in
hydrochloride buffer for 30 minutes, washed with distilled water, and then placed in
denaturing buffer for two 20-minute washes. DNA was transferred onto a Nylon Hybond
–N+ membrane (GE Healthcare, Pittsburgh, PA) overnight. DNA was cross-linked onto
the membrane, which was then pre-hybridized for 1-2 hours before adding probe. The
radioactive
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P-labeled probe was created using a portion of the AAVS1-Puro donor

plasmid after digestion with BamHI that corresponds to the AAVS1 left homology arm of
the plasmid, with the following sequence: GATCCTCCCCGTGTCTGGGTCCTCTCCGGGCATCTCTCCTCCCTCACCCAACCCCATGCCGTCTTCACTCGCTGGGTTCCCTTTT
CCTTCTCCTTCTGGGGCCTGTGCCATCTCTCGTTTCTTAGGATGGCCTTCTCCGAC
GGATGTCTCCCTTGCGTCCCGCCTCCCCTTCTTGTAGGCCTGCATCATCACCGTTT
TTCTGGACAACCCCAAAGTACCCCGTCTCCCTGGCTTTAGCCACCTCTCCATCCTC
TTGCTTTCTTTGCCTGGACACCCCGTTCTCCTGTGGATTCGGGTCACCTCTCACTC
CTTTCATTTGGGCAGCTCCCCTACCCCCCTTACCTCTCTAGTCTGTGCTAGCTCTTC
CAGCCCCCTGTCATGGCATCTTCCAGGGGTCCGAGAGCTCAGCTAGTCTTCTTCCT
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CCAACCCGGGCCCCTATGTCCACTTCAGGACAGCATGTTTGCTGCCTCCAGG. After
overnight hybridization with the probe, the membrane was washed and exposed on film
for visualization.
The FLI1+/- iPSC line was confirmed via sequencing (Figure 2.6). Selected clones
were passaged 3 times before gDNA was purified using the DNeasy Blood & Tissue Kit.
Primers

flanking

the

target

site

at

exon

2

(Forward:

5’-CGACGAGTCC-

CTCTTTGACTCAG-3’, Reverse: 5’-AGCCCCATCTGCTGCAAAAAC-3’) were used for
polymerase chain reaction (PCR). Sequencing of the isolated PCR products was
performed to confirm gene editing.

CRISPR/Cas9 constructs targeting FLI1 and ETS1
While a few failed attempts at creating a FLI1+/- iPSC line using the same TALEN
strategy were being performed, CRISPR/Cas9 technology was developed for even faster
and more efficient gene editing. CRISPR gRNAs targeting either the same TALENtargeted exon 2 of FLI1 or exon 2 of ETS1 were designed using the MIT CRISPR Design
website (http://crispr.mit.edu). After submitting the exon 2 target sequences, gRNAs
were selected (Table 2.3) based on their low off-target probability. Additionally, to
decrease off-target effects, I used a strategy involving transfection of a D10A mutant
version of Cas9 that only creates a single-strand break (Cas9n), requiring the presence
of 2 gRNAs for 2 Cas9n proteins to nick opposite strands of DNA. All components of this
CRISPR/Cas9n system are contained in a single vector that was transiently transfected
into WT iPSCs (Figure 2.9).
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The single CRISPR/Cas9n vector containing either 2 gRNAs targeting exon 2 of
FLI1 or 2 gRNAs targeting exon 2 of ETS1, the Cas9n transgene and an enhanced GFP
(eGFP) transgene was transfected into WT iPSCs, adapted from the liposomal
transfection protocol for AAVS1 targeting plasmids. eGFP positive cells were detected
and single-cell sorted 24-48 hours post transfection. After culturing for 1-2 weeks, 12
iPSC clones each for FLI1 or ETS1 were mechanically picked as described above.
Similar to the TALEN protocol for sequencing of clones, gDNA was purified and the
sequence of interest amplified via PCR using primers flanking the targeted sequence
(FLI1

Forward:

5’-CTTGCTTGGGTGAAGAGTGAC-3’,

FLI1

Reverse:

5’-

CCTCTCTGCCTTAGCTCT-CTAG-3’, ETS1 Forward: 5’- TGCCTTCTTACAGCCCATTTG-3’, ETS1 Reverse: 5’- CAGGCAAGTTTGAGGACCAC-3’) before submission for
sequencing.

Study approval
Animal studies and human tissue sampling were done in accordance with
CHOP’s Institutional Animal Care and Use Committee and Institutional Review Board,
respectively.

Results
Reprogramming of WT and PTSx primary cells into iPSCs
The WT and PTSx iPSC lines were previously created at the CHOP Human
Pluripotent Stem Cell Core using two different techniques. The WT line was
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reprogramed from bone marrow-derived CD34+ cells of a normal control donor using a
tetracycline-inducible stem cell cassette (Figure 2.1) in the presence of doxycycline140.
The PTSx line was from a baby boy who died 4 days after birth. He was diagnosed with
JSx, with a confirmed 15.3 Mbp 11qter deletion and showing other JSx clinical
phenotypic features (Table 2.1). This patient also had PTSx thrombocytopenia.
Fibroblasts were obtained after death and reprogrammed using a single excisable stem
cell cassette carrying the 4 Yamanaka TFs, which was later excised by Cre
recombinase141.
Successful reprogramming of both cell lines was demonstrated by stem cell
surface marker analysis of SSEA3, SSEA4, TRA-1-60 and TRA-1-81 by flow cytometry.
These data show the reprogrammed cells were able to express all four stem cell surface
markers at a high level (Figure 2.6A). Teratoma formation assays performed by injecting
SCID-Beige mice with these iPSCs showed the presence of all three germ layers of
endoderm, mesoderm and ectoderm in the analysis of the tumor immunohistochemistry
sections (Figure 2.6B). Furthermore, karyotype analyses of at least 20 cells per line
showed no chromosomal abnormalities after reprogramming (Figure 2.6C).

Generation of FLI1-OE WT and PTSx iPSC lines
The same overexpression strategy was employed for WT and PTSx iPSC, using
a previously published megakaryocyte-specific method115. The AAVS1 safe harbor
locus, at which gene insertions have been shown to be resistant to silencing in iPSCs as
well as having no deleterious effects reported145, was targeted for the insertion of either
1 or 2 copies of the AAVS1-Gp1ba-hFLI1 vector containing primary FLI1 cDNA driven by
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the mouse Gp1ba promoter. After successful puromycin selection of approximately 12
clones per line, Southern Blot analysis was performed to confirm presence of transgene.
While there were some iPSC clones that contained off-target DNA, correct insertion of
FLI1 was confirmed for both WT and PTSx lines (Figure 2.8). Henceforth, the single FLI1
transgene insertion will be named WT-OE1 and PTSx-OE for WT and PTSx lines,
respectively. The double transgene insertion will be named WT-OE2 for the WT line.

Generation of the heterozygous FLI1 iPSC line from WT iPSCs
Since the TALEN plasmids did not contain a selection gene, I co-transfected cells
with the TALENs along with the ZFNs used for generation of WT-OE and PTSx-OE
iPSCs. This strategy was used in order to positively select for colonies that successfully
received the puromycin resistance gene, which means the probability that the TALEN
plasmids also entered the cell was increased. A total of 12 puromycin-resistant colonies
were selected, as described for iPSC generation above. After sequencing using primers
flanking the TALEN target site at exon 2 of FLI1, one clone with a heterozygous deletion,
73128_73129delCA, was confirmed (Figure 2.7). Further computational analysis of this
2-bp deletion showed a frameshift mutation occurring at amino acid 60 and resulting in a
premature stop codon at amino acid 69 with a hypothetical protein estimated size of 7.3
kDa146.

CRISPR/Cas9n transfections
WT iPSCs transfected with CRISPR/Cas9n in the same manner as the AAVS1and TALEN-targeted experiments expressed fluorescent eGFP 24-48 hours post
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transfection. Single cell sorting for these eGFP positive cells was performed no more
than 72 hours post transfection. These sorted cells were plated in low density on a 100mm dish containing irMEFs and eventually lost their fluorescence, indicating no
integration of vector DNA occurred. After individual clone picking and sequencing
analysis, however, no mutated clones were observed for either FLI1 or ETS1. This
experiment was repeated three times, including once where the puromycin resistance
gene was used for selection instead of eGFP.

Discussion
Generation of self-renewing and pluripotent iPSC lines from human somatic cells
has opened the door to many studies not possible before. While these cell lines do not
fully capture the complete physiology of in vivo cells, they do allow for in depth analysis
of pathogenesis of rare or hard to model diseases. Moreover, with new gene editing
technologies like TALENs and CRISPR/Cas9, it is possible to easily create additional
isogenic iPSC lines, having the same genetic background that was generated from a
single individual. In this study, I used a control WT and a PTSx patient iPSC created at
CHOP as tools to answer key questions about FLI1 biology in megakaryopoiesis. For
further and detailed studies that ask the question of whether or how varying levels of
FLI1 would impact megakaryocytes and platelets, I used ZFNs and TALENs to gene edit
both WT and PTSx iPSC lines to either have increased or decreased FLI1 expression
with controlled genotypic backgrounds.
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Methods for the successful generation of iPSCs have been studied and
developed rigorously in the past decade140,141,147. The ideal reprogramming technique
would be either virus-free or integration free so as to not disrupt the genome, causing
unintended deleterious effects. I used two iPSC lines in my thesis that were created
using integrating viral constructs, but the reprogramming genes can either be induced140
or excised141. These methods minimize the disruption of functional genes in these lines.
Standard pluripotency analyses of these two lines were performed: stem cell markers
(Figure 2.6A), teratoma formation (Figure 2.6B), karyotyping (Figure 2.6C). Flow
cytometry data show normal expression of stem cell surface markers SSEA3, SSEA4,
TRA-1-60 and TRA-1-81. Teratoma tumor formation assays done in SCID-Beige mice
proved the ability of the iPSCs to differentiate into endoderm, mesoderm and ectoderm
lineages, as seen in immunohistochemistry tissue sections. Finally, the reprogramming
methods used to generate the WT and PTSx iPSC lines did not alter the genomic
integrity and stability of these cells. This was shown through the normal karyotypes
obtained from representative cells.
From the two WT and PTSx iPSC lines, I utilized various gene-editing strategies
to create isogenic FLI1 overexpression or FLI1 heterozygous mutation lines. Starting
with the WT and PTSx iPSCs, ZFNs targeting the AAVS1 safe harbor locus and a donor
plasmid containing the FLI1 transgene driven by the murine Gp1ba promoter were
transfected to generate overexpression of FLI1 in a megakaryocyte-specific manner.
This strategy has proven to be successful in our laboratory for the megakaryocytespecific expression of both eGFP and αIIb115. Confirmation of the insertion was done
through Southern Blot analysis of gDNA from the resulting iPSC clones (Figure 2.8).
Integration of the FLI1 donor plasmid was indeed successful for many of the selected
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iPSC clones, along with clones containing off-target integration. I selected 2 WT-OE
iPSC clones for further in vitro and in vivo studies: WT-OE1 and WT-OE2, containing 1
or 2 copies of transgene that was correctly integrated into the genome, respectively. The
PTSx-OE clone selected for further studies contained 1 copy of correctly integrated
transgene.
For the disruption of FLI1 in WT iPSCs, I used TALEN technology in combination
with the AAVS1-targeting ZFNs. At the time, the field of TALEN gene editing was still
very novel and, while they are much easier to construct than ZFNs127, their efficiency can
be very low due to sensitivity to cytosine methylation, a known mechanism of DNA
silencing148. The TALEN containing plasmids used for this study had no positive or
negative selection marker, so we relied on the ZFNs used above in conjunction with a
donor plasmid carrying the puromycin resistance gene. This strategy exploits the
hypothesis that if the ZFN and donor plasmids were able to enter the cell and integrate
into the AAVS1 locus, the TALEN plasmids more than likely have also entered the cell.
Unfortunately, the efficiency of this method was low, with only one puromycin resistant
WT iPSC clone containing a TALEN-mutated sequence on one allele of FLI1. This
heterozygous clone was named FLI1+/- and used in our subsequent megakaryopoiesis
studies.
A FLI1-/- iPSC line is of interest to our group, as there are no known reports of
homozygous loss of FLI1 in humans, although there is a single report of homozygous
inheritance pattern for FLI1 with a R324W mutation in the DNA-binding domain85.
Multiple attempts at creating a WT-derived FLI1-/- iPSC line using the TALENs above
were unsuccessful. Therefore, I employed the CRISPR/Cas9 technology that has since
emerged to be a fast and efficient method for gene editing. To address the high off40

target mutations attributed to a tolerance of single base mismatches149, I used a D10A
Cas9 (Cas9n) endonuclease that only creates single-strand breaks150. This method
reduces off-target effects by requiring a pair of gRNAs binding on opposite strands of
DNA, guiding the Cas9n to nick both strands at the intended target site. Because these
gRNAs are relatively easy to design, in addition to targeting FLI1, I also generated a pair
of gRNAs to target exon 2 of ETS1, hoping to create either iPSCs with the following
genotypes: ETS1+/-, ETS1-/-, or FLI1+/-ETS1+/-. As with TALENs, multiple attempts at
gene editing using CRISPR/Cas9n yielded no mutagenesis. These negative results are
perhaps due to the low efficiency of the 2 pairs of gRNAs designed. Alternatively, the
FLI1 and ETS1 genes may be undiscovered essential genes for cellular viability. For
further conclusions about efficiency or gene essentiality, more gRNAs targeting other
sites on these genes need to be tested. Unfortunately, it was not possible for me to
further pursue optimizing this CRISPR/Cas9n protocol as part of my thesis. Moreover,
the iPSC lines that were already successfully generated allowed a complete and
comprehensive testing of our overall hypothesis that FLI1 expression levels during
megakaryopoiesis positively correlates with megakaryocyte maturation, subsequent in
vivo thrombopoiesis and released platelet quality.
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Tables

Clinical Description

PTSx patient

Platelet count

61 – 83 X 10 /µl

150 – 400 X 10 /µl

Mean platelet volume

9.1 – 9.8 fl

7.4 – 10.4 fl

3

3

Reference range
3

3

White blood cell count

10.7 – 18.8 X 10 /µl

9.0 – 30.0 X 10 /µl

Hemoglobin

16.4 – 17.6 g/dl

14.5 – 22.0 g/dl

Other clinical
manifestations

Jacobsen’s syndrome, hypoplastic left heart syndrome,
intrauterine growth restriction and dysmorphic features

Table 2.1. Hematologic and other data of the patient with PTSx.
Description of the patient diagnosed with PTSx. This patient was a newborn male with a
15.3 Mbp hemizygous deletion at chr11:119,574,140-134,940,416 in hg19. Data were
collected prior to the patient expiring at 4 days of life, at which time fibroblasts were
obtained and used to create iPSCs.
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Target

Source

SSEA-3
SSEA-4
TRA-1-60
TRA-1-81

Table

2.2.

Polyclonal
rat
Polyclonal
mouse
Polyclonal
mouse
Polyclonal
mouse

List

of

Reactivity

Label

Company

Catalog number

Usage

Human

AF 488

Biolegend

330306

Flow cytometry

Human

AF 647

Biolegend

330408

Flow cytometry

Human

AF 488

Biolegend

330614

Flow cytometry

Human

AF 647

Biolegend

330706

Flow cytometry

antibodies

used

for

iPSC

pluripotency

analysis.

Description of antibodies used for stem cell surface marker analysis via flow cytometry.
Alexa Fluor is abbreviated as AF.
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Targeted Gene

gRNA Sequence

Strand Orientation

FLI1

5’-AGGCCGACATGACTGCCTCGGGG-3’

Forward

FLI1

5’-CTCCGTACGCTGAGTCAAAGAGG-3’

Reverse

ETS1

5’-GCATTAAAAGCTACTTTCAGTGG-3’

Forward

ETS1

5’-TTGCTGCTTGGAGTTAATAGTGG-3’

Reverse

Table 2.3. gRNA pairs designed for disruption of FLI1 and ETS1.
One pair of gRNAs was designed to target either FLI1 or ETS1, both at exon 2 of each
gene. These tandem gRNAs were used with a nickase mutant of Cas9, Cas9n.
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Figures

5’ LTR PSI

miniCMV
TetO
HIV cpPu
RRE
Oct4 F2A

dU3
KLF4

IRES

Sox2

E2A

cMyc

WPRE

3’ LTR

STEMCCA
Figure 2.1. Vector schematic of the tetracycline-inducible expression cassette.
iPSC generation using an inducible stem cell cassette pHAGE-Tet-hSTEMCCA. Vector
schematic

illustrating

the

pHAGE-Tet-hSTEMCCA

plasmid

containing

the

4

reprograming genes. This stem cell cassette consists of a single multicistronic mRNA
transcribed under the control of a tetracycline-inducible TetO-miniCMV promoter.
Abbreviations: cpPu, central polypuryne tract; dU3, deleted U3; HIV, human
immunodeficiency virus; IRES, internal ribosome entry site; LTR, long terminal repeat;
miniCMV, mini-cytomegalovirus; PSI, packaging signal; RRE, rev responsive element;
STEMCCA, stem cell cassette; WPRE, woodchuck hepatitis virus post-transcriptional
regulatory element.

Adapted from Sommer et al. Stem Cells. 2009
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T

1732

A

B
EF1a promoter

CRE_NLS

IRES

Puro

Figure 2.2. Vector schematics of the single excisable lentiviral stem cell
reprogramming cassette and Cre-IRES-Puro plasmid.
iPSC generation using a single excisable lentiviral stem cell cassette (hSTEMCCA-loxP).
(A) Vector schematic illustrating the lentiviral backbone containing human cDNA
sequences of the four reprogramming factors. A loxP site inserted in the viral 3’LTR is
duplicated to the 5’LTR during viral infection and reverse transcription. (B) Vector
schematic illustrating the plasmid for transient expression of the genes for Cre
recombinase and puromycin resistance. The floxed hSTEMCCA-loxP vector integrated
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Figure 1. Human induced pluripotent stem cell (iPSC) generation using a hu
loxP). (A): Vector schematic illustrating the polycistronic lentiviral backbone
mCherry. A loxP site inserted in the viral 30 LTR is duplicated to the 50 LTR durin
tor integrated in the host mammalian genome can then be excised on exposure to
ture (left panel) and reprogrammed human iPSC colonies (right panel). Multiple

in the host mammalian genome can be excised on exposure to Cre recombinase
Abbreviations: See Figure 2.1 and CMYC, cellular myelocytomatosis oncogene; EF1a,
elongation factor 1 alpha constitutive promoter; hSTEMCCA, humanized version of the
single lentiviral stem cell cassette; NLS, nuclear localization signal; PRE, posttranscriptional regulatory element; Puro, puromycin resistance gene; RT, reverse
transcription.

Adapted from Somers et al. Stem Cells. 2010
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A
PGK promoter

ZFN-L

PGK promoter

ZFN-R

B

C
HA-L

Puro

Gp1ba promoter

FLI1

HA-R

Figure 2.3. Vector schematics the AAVS1-targeting ZFN and donor plasmids for
FLI1 overexpression.
Generation of FLI1 overexpression iPSCs. (A and B) Vector schematics illustrating the
pPGK-AAVS1-ZFNL and pPGK-AAVS1-ZFNR plasmids containing the ZFNs that target
the HA-L or HA-R, respectively, on the AAVS1 locus, with both being driven by the
constitutive PGK promoter144. (C) Vector schematic illustrating the AAVS1-Gp1ba-hFLI1
donor plasmid containing homology arms to the AAVS1 locus, puromycin resistance
gene and FLI1 cDNA driven by the Gp1ba promoter. Abbreviations: HA, AAVS1
homology arm; L, left; PGK, phosphoglycerate kinase; R, right; ZFN, zinc finger
nuclease.
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Figure 2.4. FLI1 cDNA sequence used for transgene overexpression.
ATGGACGGGACTATTAAGGAGGCTCTGTCGGTGGTGAGCGACGACCAGTCCCTCT
TTGACTCAGCGTACGGAGCGGCAGCCCATCTCCCCAAGGCCGACATGACTGCCTC
GGGGAGTCCTGACTACGGGCAGCCCCACAAGATCAACCCCCTCCCACCACAGCAG
GAGTGGATCAATCAGCCAGTGAGGGTCAACGTCAAGCGGGAGTATGACCACATGA
ATGGATCCAGGGAGTCTCCGGTGGACTGCAGCGTTAGCAAATGCAGCAAGCTGGT
GGGCGGAGGCGAGTCCAACCCCATGAACTACAACAGCTATATGGACGAGAAGAAT
GGCCCCCCTCCTCCCAACATGACCACCAACGAGAGGAGAGTCATCGTCCCCGCAG
ACCCCACACTGTGGACACAGGAGCATGTGAGGCAATGGCTGGAGTGGGCCATAAA
GGAGTACAGCTTGATGGAGATCGACACATCCTTTTTCCAGAACATGGATGGCAAGG
AACTGTGTAAAATGAACAAGGAGGACTTCCTCCGCGCCACCACCCTCTACAACACG
GAAGTGCTGTTGTCACACCTCAGTTACCTCAGGGAAAGTTCACTGCTGGCCTATAA
TACAACCTCCCACACCGACCAATCCTCACGATTGAGTGTCAAAGAAGACCCTTCTTA
TGACTCAGTCAGAAGAGGAGCTTGGGGCAATAACATGAATTCTGGCCTCAACAAAA
GTCCTCCCCTTGGAGGGGCACAAACGATCAGTAAGAATACAGAGCAACGGCCCCA
GCCAGATCCGTATCAGATCCTGGGCCCGACCAGCAGTCGCCTAGCCAACCCTGGA
AGCGGGCAGATCCAGCTGTGGCAATTCCTCCTGGAGCTGCTCTCCGACAGCGCCA
ACGCCAGCTGTATCACCTGGGAGGGGACCAACGGGGAGTTCAAAATGACGGACCC
CGATGAGGTGGCCAGGCGCTGGGGCGAGCGGAAAAGCAAGCCCAACATGAATTA
CGACAAGCTGAGCCGGGCCCTCCGTTATTACTATGATAAAAACATTATGACCAAAG
TGCACGGCAAAAGATATGCTTACAAATTTGACTTCCACGGCATTGCCCAGGCTCTG
CAGCCACATCCGACCGAGTCGTCCATGTACAAGTACCCTTCTGACATCTCCTACAT
GCCTTCCTACCATGCCCACCAGCAGAAGGTGAACTTTGTCCCTCCCCATCCATCCT
CCATGCCTGTCACTTCCTCCAGCTTCTTTGGAGCCGCATCACAATACTGGACCTCC
CCCACGGGGGGAATCTACCCCAACCCCAACGTCCCCCGCCATCCTAACACCCACG
TGCCTTCACACTTAGGCAGCTACTACTAG
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500 µm

Figure 2.5. iPSC morphology.
Representative iPSC colony depicting typical morphology of the clones selected for
further cell culture. Black arrows indicate iPSC colonies and white arrows indicate
irradiated mouse embryonic fibroblast feeder layer. Brightfield image taken at 40X using
a Zeiss Axio Observer 7.1 microscope.
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Figure 2.7. Using TALENs to mutate FLI1.
Generation of the FLI1+/- iPSC line using TALENs targeting FLI1 exon 2. (A) Schematic
of the TALEN pair targeting a site on exon 2 of FLI1 (TALEN-E2-L and TALEN-E2-R).
(B) Chromatograph depicting a heterozygous 2-nucleotide deletion (shown in red in
Figure 2.6A) confirmed by sequencing. Abbreviations: FLI1, Friend Leukemia Virus
Integration 1; TALEN-E2-L, transcription activator like effector nuclease targeting FLI1
exon 2, left strand; TALEN-E2-R, transcription activator like effector nuclease targeting
FLI1 exon 2, right strand.
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Figure 2.8. Genomic DNA analysis for the confirmation of correct GP1ba-FLI1
transgene insertion.
Southern Blot analysis of WT and PTSx iPSC clones generated after AAVS1-targeted
FLI1 overexpression. (A) Schematic illustrating the Southern Blot assay experimental set
up. The 5’

32

P probe binds to an endogenous region in the AAVS1 locus, flanked by two

SphI restriction sites. When the transgene had been successfully inserted at the right
position, a new SphI restriction site on the plasmid DNA will allow for a smaller DNA
fragment. (B) Southern Blot membrane image of the various iPSC lines generated postSphl digestion. The 6.5 kb long gDNA band is endogenous allele without targeting, and
runs slower than the 3.8 kb transgene band that represents a targeted allele.
Abbreviations: See Figure 2.3 and PTSx, Paris Trousseau syndrome patient iPSC line;
PTSx-OE, PTSx iPSC line with one allele targeted; WT-OE1, normal control WT iPSC
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line with one allele targeted; WT-OE2, normal control WT iPSC line with both alleles
targeted.
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Figure 2.9. Vector schematic of CRISPR/Cas9n.
Schematic illustrating the single CRISPR/Cas9n vector containing the 2 gRNAs, the
nickase Cas9n and either a puromycin resistance or eGFP selection gene.
Abbreviations: Same as Figures 2.2 and 2.3 and CHYSEL, cis-acting hydrolase element;
eGFP, enhanced green fluorescent protein.
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CHAPTER 3 – In vitro analysis of FLI1-modified iPSC-derived
megakaryocytes and platelets
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Abstract
We studied induced pluripotent stem cell (iPSC)-derived megakaryocytes (iMegs)
to better understand clinical PTSx and FLI1 mutation disorders using iPSC lines
generated from a PTSx patient and from a targeted heterozygous FLI1 knockout (FLI1+/-)
in a control line. PTSx and FLI1+/- iMegs replicate many of the megakaryocyte and
platelet features previously described with a decrease in iMeg yield, cell size and ploidy.
These iMegs had lower levels of mature megakaryocyte surface marker expression as
well as increased levels of markers of in vitro iMeg injury. We noted that the closelylinked ETS Proto-Oncogene 1 (ETS1) and ETS Variant 6 (ETV6) TFs have increased
and decreased expression, respectively, in FLI1-deficient iMegs. The inverse FLI1/ETS1
levels suggest that FLI1 negatively regulates ETS1 in megakaryopoiesis. Finally, we
examined

whether

FLI1

overexpression

would

affect

megakaryopoiesis

and

thrombopoiesis. We found an increased yield of non-injured in vitro iMegs as well as
higher ploidy and cell size. These studies confirm FLI1 heterozygosity results in
pleiotropic defects similar to those noted with other critical megakaryocyte-specific TFs,
but that its overexpression does not alter megakaryopoiesis, which differs from that seen
with GATA1 overexpression in a murine setting.
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Introduction
The current literature on megakaryocyte and platelet defects associated with
PTSx, and also a growing number of reports of FLI1 mutations, provide clinical
descriptions to the degree of the macrothrombocytopenia, platelet ultrastructure analysis
and findings of immature micromegakaryocytes either in bone marrow or cultured
progenitors78,79,151. A next generation sequencing study done on 13 families with
inherited platelet disorder that found 3 different FLI1 mutations in the DNA-binding
domain84 included platelet aggregation analysis of one of the FLI1-deficient families. The
single report of a homozygous FLI1 mutation causing PTSx-like platelet features
presents data on a defect in collagen-induced platelet aggregation as well as on
decreased platelet protein expression of GPVI, GPIX and GPIIb (or αIIb). Both reports
used the human embryonic kidney cell line HEK293 to test the TF activity of the mutated
FLI1 proteins.
These studies, while informative and highlight the clinical implications of FLI1
influence on megakaryocytes and platelets, provide only limited insights into the cellular
defects and do not provide comparison analyses to a common genotypic control. To
date, there had only been one report of in vitro analysis of FLI1 biology on
megakaryopoiesis: a PTSx primary CD34+ cell study on 2 patients82. It is not surprising
that there are not more detailed reports on PTSx and FLI1 mutation megakaryocytes
and platelets. These patients are rare and harvesting enough cells to experiment on is a
challenge. We approached this challenge with the use of iMegs.
Our group had previously used iPSCs to study iMegs in the setting of Glanzmann
Thrombasthenia (GT)115, a rare autosomal recessive disease resulting in the lack of
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functional platelet integrin αIIbβ3152. GT patients present with a bleeding diathesis due to
the integral role of αIIbβ3 in platelet aggregation153. By using the described murine
Gp1ba promoter to drive expression of the αIIb transgene, iMeg surface expression of
αIIbβ3 was restored in iPSC lines generated from two GT patients with mutations in αIIb.
These gene-corrected GT iPSC lines showed functional αIIbβ3 biological activity upon
activation of iMegs by a known platelet activator via the collagen receptor GPVI,
convulxin154. With this proof-of-principle study in mind, we used the same system to
overexpress FLI1 in PTSx patient-derived and WT iPSCs, and created WT iPSCs that
either lack one functional copy of FLI1 or express extra copies of FLI1. This strategy
allows for creation of iPSC lines from the same genetic background with varying levels of
FLI1 expression. This Chapter outlines the use of the described FLI1-modified iPSC
lines to study megakaryopoiesis and in vitro characteristics of the resulting
megakaryocytes. In vivo studies of these iMegs are described in Chapter 4.

Methods
Differentiation of iPSCs into megakaryocytes
iPSC lines were maintained in iPSC medium with an irMEF feeder layer, as
described in Chapter 2. Before differentiation into HPCs, iPSCs were transitioned to a
feeder-free system in mTESR-1 medium (Stem Cell Technologies, Vancouver, Canada)
for at least 4 passages. Confluent cells were gently detached using 1 U dispase (Stem
Cell Technologies) per 35-mm culture dish for 6-8 minutes at 37°C then washed 2X with
RT DMEM/F12. They were then mechanically scraped off and centrifuged at 1200 rpm
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for 3 minutes. Cells were then resuspended in RT mTESR-1 medium and plated at a 1:3
to 1:9 ratio onto plates pre-coated with Matrigel hESC-qualified matrix (Corning).
Hematopoietic differentiation of iPSCs to HPCs was performed as previously
described115,143. Differentiation starts on Day 0 by feeding iPSCs plated the day before
(Day -1) with 4 ml per 35-mm dish with Roswell Park Memorial Institute medium (RPMI,
Gibco) supplemented with 1mM L-glutamine (Sigma-Aldrich), 50 μg/ml ascorbic acid
(Wako Chemicals, Richmond, VA), 3 μl/ml monothiolglycerol (MTG, Sigma-Aldrich), 5
ng/ml Bone Morphogenic Protein 4 (BMP4, Stemgent, Cambridge, MA), 50 ng/ml
Vascular Endothelial Growth Factor (VEGF, R&D Systems) and 1 μM Glycogen
Synthase Kinase 3 inhibitor CHIR (Tocris). On Day 2, cells were washed once with
RPMI and fed with 4 ml per 35-mm dish with 1:1 RPMI and StemPro-34 serum-free
medium (SP34, Gibco) supplemented with 1mM L-glutamine, 50 μg/ml ascorbic acid, 3
μl/ml MTG, 5 ng/ml BMP4, 50 ng/ml VEGF and 20 ng/ml bFGF. On Day 4, cells were fed
with 4 ml per 35-mm dish with SP34 supplemented with 1mM L-glutamine, 50 μg/ml
ascorbic acid, 3 μl/ml MTG, 15 ng/ml VEGF and 5 ng/ml bFGF. On Day 6, cells were
washed once with IMDM and fed with 3 ml per 35-mm dish with serum-free
differentiation medium (SFD: 75% IMDM; 1% B-27 and 0.5% N-2 supplements,
Invitrogen; 1 mM (1%) L-glutamine; 0.5% BSA; and 22% Hams F12 medium, Corning)
containing 50 μg/ml ascorbic acid, 3 μl/ml MTG, 50 ng/ml VEGF, 100 ng/ml bFGF, 10
ng/ml IL-6, 50 ng/ml TPO (R&D Systems), 25 ng/ml Fms-Like Tyrosine Kinase 3 Ligand
(FLT-3L, Gibco) and 25 ng/ml Stem Cell Factor (SCF, Gibco). HPCs in suspension were
collected from the culture dish supernatant at Days 7 or 8.
Differentiation of HPCs into iMegs was as previously described143. Collected
HPCs at Days 7 or 8 of differentiation were cultured in SFD medium supplemented with
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50 μg/ml ascorbic acid, 3 μl/ml MTG, 25 ng/ml SCF and 100 ng/ml TPO (Day 0 of iMeg
differentiation). This medium was changed on Day 3 to SFD medium supplemented with
50 μg/ml ascorbic acid, 3 μl/ml MTG, 1 ng/ml SCF and 100 ng/ml TPO, 10 ng/ml IL-6
and 13.5 ng/ml IL-9. iMegs were collected on Day 5 for in vitro analysis.

Flow cytometry analysis of iMegs and other cells
iMegs and in vitro-derived platelet particles were stained as described in Chapter
2. Data were collected with a BD FACSCanto II and analyzed using FlowJo software.
Antibodies used in this study for FACS analysis and other studies are detailed in Table
3.1. Ploidy was assessed via flow cytometry after incubating live cells with Vibrant
DyeCycle Green DNA dye (Thermo Fisher Scientific) at 37°C for 30 minutes.

Analysis of megakaryocyte mRNA and protein levels
iMegs were selected using the AutoMACS Pro (Miltenyi, Bergisch Gladbach,
Germany) after staining with a primary phycoerythrin (PE)-labeled, anti-human CD41a
antibody (BD Biosciences, Table 3.1) and secondary anti-PE microbeads (Miltenyi).
RNA isolation was performed using the RNeasy isolation kit (Qiagen), after which cDNA
synthesis was performed using the high capacity cDNA synthesis kit (Life Technologies,
Carlsbad, CA). Taqman probes for GAPDH (Hs02758991_g1), FLI1 (Hs00956711_m1),
ETS1 (Hs00428293_m1), ETV6 (Hs00231101_m1), RUNX1 (Hs02558380_s1), ITGA2B
(Hs01116228_m1),

GP9

(Hs01040883_g1),

PF4

(Hs00427220_g1),

and

MPL

(Hs00180489_m1) were used for quantitative real-time PCR (qRT-PCR) on a 7900HT
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Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). Data were analyzed
using the 2-ΔΔCT method155.
Western Blot analyses on CD41a-selected iMegs were performed after protein
extraction using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific,
Waltham, MA). Lysate protein concentrations were then determined using the
bicinchoninic acid protein assay kit (Thermo Scientific). NuPAGE LDS Sample Buffer
(Invitrogen), containing lithium dodecyl sulfate at pH 8.4 and 5% added βmercaptoethanol (Sigma-Aldrich), was mixed with protein samples and loaded into 412% NuPAGE Bis-Tris precast gels (Invitrogen) under reducing conditions. Proteins
were separated by gel electrophoresis and transferred onto polyvinylidene fluoride
membranes with the iBlot Dry Blotting System (Invitrogen). Membranes were blocked in
5% nonfat dry milk in PBS with 0.01% Tween 20 (PBST, BioRad, Hercules, CA) for 1
hour at RT, followed by primary antibody incubation in 1% nonfat dry milk in PBST
overnight at 4°C. The next day, membranes were washed with PBST for 15 minutes 3X
to remove excess antibody, then incubated with the appropriate secondary antibody
conjugated to horseradish peroxidase at RT for 1 hour. After washing 3X with PBST,
membranes were developed using the SuperSignal West Pico Chemiiluminescent
Substrate detection system (Thermo Scientific). Antibodies shown in Table 3.1 were
used at the indicated volume/volume (v/v) dilutions: FLI1 (1:2000), PF4 (1:15,000) and
TATA-box binding protein (1:2000). Secondary antibodies were horseradish peroxidasegoat anti-rabbit IgG (1:10,000) and horseradish peroxidase-goat anti-mouse IgG
(1:10,000).
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Hematopoietic colony-forming assays and liquid expansion of HPCs to iMegs
Single cell HPCs collected from the iPSC differentiation medium were used in
methylcellulose and Megacult colony assays (Stem Cell Technologies) according to
manufacturer instructions. Flow cytometry for CD41a and CD235a surface markers were
used to determine purity and absolute number of HPCs. Expansion to iMegs was
performed by plating 5 X 105 HPCs per 35-mm well in SFD medium, as described
above. After 5 days, the quality and absolute number of iMegs were calculated from the
percentage of cells expressing surface CD41a, CD42a, CD42b and annexin V via flow
cytometry.

Transmission electron microscopy (TEM) analysis of iMegs
iMeg samples for ultrastructure analysis were fixed with 2.5% glutaraldehyde,
2.0% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, overnight at 4°C.
Samples were post-fixed in 2.0% osmium tetroxide for 1 hour at room temperature, and
washed in the same cacodylate buffer followed by deionized H2O. After dehydration
through a graded ethanol series, the tissue was infiltrated and embedded in EMbed-812
(Electron Microscopy Sciences) at the University of Pennsylvania Electron Microscopy
Resource Laboratory (Philadelphia, PA). Thin sections were stained with uranyl acetate
and lead citrate and examined with a JEOL 1010 electron microscope fitted with a
Hamamatsu digital camera and AMT Advantage image capture software.

Statistical analysis
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Statistical analysis was performed using one-way ANOVA and data was reported
as mean ± 1 standard error of the mean (SEM) using the GraphPad Prism software
version 6.00 for Mac (GraphPad Software, La Jolla, CA). Differences were considered
significant when the P value was less than 0.05.

Study approval
Animal studies and human tissue sampling were done in accordance with
CHOP’s Institutional Animal Care and Use Committee and Institutional Review Board,
respectively.

Results
Establishment and characterization of iMegs with differing levels of FLI1
To evaluate whether the megakaryocyte and platelet defects observed in patients
with PTSx are specifically due to FLI1 expression levels, patient-specific and geneedited iPSC lines were created as described in Chapter 2 and summarized in Table 3.2.
Briefly, a normal control iPSC line, labeled WT, was used to create three additional
isogenic lines: a single allele insertion of FLI1 transgene at the AAVS1 locus (WT-OE1),
a double allele insertion of FLI1 transgene at the AAVS1 locus (WT-OE2) and a
heterozygous FLI1 mutation (FLI1+/-) in exon 2 resulting in a markedly truncated protein
with 53 normal N-terminal amino acids followed by the frameshift mutation containing 10
amino acids. The endogenous protein is 452 amino acids long. A PTSx patient iPSC
was also used to generate a PTSx-OE line that had a single insertion of FLI1 transgene
65

at the AAVS1 locus. These 6 iPSC lines were then differentiated along the
hematopoietic lineage into HPCs and eventually to iMegs.
The expected differences in FLI1 mRNA expression levels were confirmed in
iMegs derived from these different lines (Figure 3.1A). During the 5-day expansion of
HPCs to iMegs in the OE lines, FLI1 mRNA expression was increased compared to their
respective parental lines. Although the Gp1ba promoter is a late megakaryocyte
promoter, we have previously shown that it is also active in the iPSC-derived progenitor
cell115. FLI1 mRNA expression in the PTSx and FLI1+/- lines started out at approximately
half of WT on day 1, but gradually increased as differentiation progressed. FLI1 protein
levels measured on Day 5 of differentiation in the various lines were consistent with the
genotypes of these lines (Figure 3.1B).
In addition to FLI1, mRNA levels of TFs known to be important in
megakaryopoiesis (ETS1, ETV6 and RUNX1) (Figure 3.2) and several megakaryocytespecific genes (MPL, MYH10, GP9, ITGA2B, and PF4) (Figures 3.3 and 3.4A) were also
examined throughout the 5 days of iMeg expansion. After day 1, ETS1 levels were
inversely related with the level of FLI1 in the developing megakaryocytes. ETS1 is
physically close to FLI180 and is deleted along with FLI1 in PTSx. There has been
speculation as to whether the PTSx phenotype is related to haploinsufficiency of ETS1
as well as FLI181. However, in spite of having only one copy of ETS1, PTSx
megakaryocytes have an excess rather than a deficiency of ETS1 TF. Primary
megakaryocyte ChIP-Seq data156 demonstrated a FLI1-binding site ~100 kb downstream
of ETS1 (Figure 3.3A). Markers of active enhancers, including H3K4me1 and
H3K27ac157, also localized to this site158. This region was annotated by ChromHMM as
‘enhancer’ chromatin in several cell types159. Together, this pattern could indicate a
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regulatory mechanism by which FLI1 binding mediates suppression of ETS1 (Figure
3.3B).
The other TFs and megakaryocyte-specific proteins either correlated with or
showed no clear relationship to FLI1 mRNA expression levels. A correlative relationship
in mRNA levels was seen for ETV6 (Figure 3.2), another ETS family member whose
haploinsufficiency also results in a quantitative platelet disorder160. MPL mRNA levels
also correlated with FLI1 mRNA levels (Figures 3.1A and 3.4A). Surface MPL protein
levels in iMegs at days 2 to 5 of differentiation (Figure 3.4B) were decreased in the
FLI1+/- and PTSX lines, consistent with reports of decreased MPL after FLI1 mutation85
and of MPL as a direct target gene of FLI1161. MYH10 transcript was increased during
iMeg differentiation in the FLI1-low lines, reflecting reports of increased MYH10, silenced
during normal megakaryocyte polyploidization and maturation162, in PTSx patient
platelets84,85,163. Levels of PF4 protein were comparable in all lines (Figure 3.4B). Levels
of RUNX1, GP9, ITGA2B and PF4 transcripts were normal. GP9, ITGA2B and PF4 have
all been reported as direct targets of FLI1161,164, but also are increased as a result of
ETS1 overexpression during megakaryopoiesis20. Perhaps the unexpectedly high ETS1
levels compensate for the decreased FLI1 levels for these genes.

Effect of FLI1 on megakaryocyte and other lineage potential
To assess the effect of FLI1 on megakaryocyte clonogenic potential, a
hematopoietic colony-forming assay in a collagen-based culture system165 was used to
analyze the yield of large and small megakaryocyte colony-forming units (CFU-MKs). In
this system, large CFU-MKs were defined as colonies containing ≥50 cells and small
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CFU-MKs as colonies containing <50 cells (Figure 3.5A). No large CFU-MKs were
generated from PTSx and FLI1+/- progenitors, whereas the level of small CFU-MKs from
these lines were ~10% and ~20% of WT, respectively. The WT-OE1 and WT-OE2 lines
had more large CFU-MKs, and significantly more small CFU-MKs compared to WT.
These findings suggest that decreased expression of FLI1 affects megakaryocyte
potential, especially large CFU-MK potential. Conversely, the overexpression of FLI1 in
both WT and PTSx lines either increased the number of small CFU-MKs or the numbers
were comparable to the parental lines. PTSx-OE large CFU-MKs were decreased
compared to WT, but small CFU-MK numbers were comparable.
The relative expansion of iMegs from HPCs in liquid culture was analyzed as
another approach to quantitatively study the effect of FLI1 levels on megakaryopoiesis.
The differentiation and expansion of HPCs to iMegs yielded results comparable to
colony formation data (Figure 3.5B): The PTSx and FLI1+/- progenitors yielded fewer
iMegs compared to WT. HPCs from the WT-OE1 and WT-OE2 lines yielded high
expansion numbers of ~150% (P = 0.08) and ~230% (P < 0.01) per HPC, respectively,
compared to WT. The PTSx-OE HPCs yielded more iMegs than parent PTSx HPCs, but
to only 63% of WT. Perhaps here, the genotypic background of the PTSx patient differed
from the WT individual affecting maximal iMegs per HPC.
The effect of FLI1 levels on myeloid and erythroid progenitor potential was also
analyzed (Figure 3.6). Myeloid progenitor potential was comparable amongst all lines,
while PTSx and FLI1+/- progenitors were biased toward the erythroid blast-forming unit
(BFU-E) and CFU-E colonies. The BFU-E and CFU-E progenitor potential of WT-OE1,
WT-OE2 and PTSx-OE HPCs was comparable or less than WT. These data support the
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known role of FLI1 driving the megakaryocyte-erythroid progenitor towards the
megakaryocyte lineage48,166.

Qualitative characterization of the effects of FLI1 on iMegs
We next examined whether the iMegs obtained from the iPSC lines differed
qualitatively as well as quantitatively. Flow cytometry analyses of megakaryocytespecific surface markers were performed for CD41a (GPIIb/IIIa or αIIbβ3), an early
marker of the megakaryocyte lineage167; CD42a (GPIX), a marker of megakaryocyte
maturation168; and CD42b (GPIX/GPIbα), an indicator of megakaryocyte injury due to
cleavage and removal of the extracellular glycocalicin domain of GPIbα169. A significantly
lower percentage of PTSx and FLI1+/- iMegs expressed CD41a, CD42a and CD42b
compared to WT (Figure 3.7A). Slightly higher percentage of WT-OE1 and WT-OE2
iMegs expressed CD41a, CD42a and CD42b compared to WT, while PTSx-OE iMegs
were comparable to WT. These data suggest that the maturation of PTSx and FLI1+/iMegs may be impaired by FLI1 heterozygous deficiency and corrected with FLI1
overexpression.
Previous studies from our group have shown that in vitro-released platelets have
poor in vitro and in vivo functionality and short in vivo half-lives due to faster clearance of
CD42b- particles in the mouse circulation170. In vitro-derived platelet particles,
corresponding in size to human donor platelets, from iMeg cultures were analyzed for
surface markers for CD41a, annexin V, and CD42b. Between 40-60% of the in vitroderived platelet particles from all lines were CD41+, but low percentages are viable
annexin V- particles (Figure 3.7B), suggesting that many of the CD41+ particles may be
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activated or injured. The low percentage of CD42a+CD42b+ platelet particles supports
that the vast majority (>85%) of in vitro platelet-like particles from all cell lines were
injured, having CD42b cleaved (Figure 3.7B).
Besides expressing megakaryocyte-specific surface markers, another indication
of maturing megakaryocytes is nuclear endoreduplication171. Overall, WT iMegs have
low ploidy compared to bone marrow mobilized CD34+-derived megakaryocytes170.
However, we saw a trend towards a decrease in 4N and >4N nuclei in the FLI1-low
iMegs and an increase in 4N and >4N in WT-OE1 and WT-OE2 iMegs relative to WT
iMegs (Figure 3.8).
As previously reported, up to 15% of PTSx platelets, but not bone marrow
megakaryocytes, have fused, giant alpha granules on electron micrographs78,79,151.
Similar platelet giant granules were observed from a family with an autosomal recessive
FLI1 mutation85. These previous reports of PTSx patient cells also show immature
micromegakaryocytes present in the bone marrow. Transmission electron microscopy
(TEM) images of FLI1+/- iMegs showed smaller cells when compared with the WT iMegs
(Table 3.3). PTSx iMegs also trended towards being small compared to WT. This
correlates with previous findings of increased micromegakaryocytes present in PTSx
patient bone-marrow samples78,79. Conversely, TEM micrographs of WT-OE2 iMegs
contained larger cells, while the size of PTSx-OE iMegs were comparable to WT iMegs.
Granules and open canalicular systems were observed in all samples, but no observable
giant granules were found in either the PTSx or FLI1+/- iMegs (Figure 3.9).
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Discussion
These in vitro studies of iPSC-derived megakaryocyte and platelet products
provide more in depth as well as novel analyses of the influences of FLI1 on
megakaryopoiesis than previously reported. While these cells do not completely
replicate many of the primary CD34+-derived megakaryocyte and platelet cellular
characteristics like high ploidy and high platelet release, they do allow for generation of
an unlimited amount of megakaryocytes and platelets for maturational, quantitative and
qualitative analyses. Furthermore, these studies can be well-controlled by using iPSC
lines of the same genetic background, as we did with the WT- and PTSx-derived iPSC
lines with low or high FLI1 expression.
With the PTSx and FLI1+/- iPSC lines, we can accurately model the PTSx and
FLI1 mutation platelet disorders while generating enough megakaryocytes and platelets
in vitro for detailed analyses. With this advantage, we show the PTSx and FLI1+/- iMegs
and platelet particles having similar defective features found in reports of primary PTSx
patient cells. HPC cells could not differentiate into megakaryocytes as effectively as
normal cells (Figure 3.5), and the ones that could mature to iMegs are primarily
damaged in vitro (Figure 3.7). These iMegs also have lower ploidy and are generally
smaller in size. For the first time, we show that FLI1+/- megakaryocytes have more than
normal ETS1 mRNA levels, while PTSx have normal levels in spite of missing a copy of
the ETS1 gene. Protein analysis was not done due to time constraints and issues with
antibodies targeting multiple isoforms of this protein. Further studies to evaluate the role
of FLI1 on ETS1 transcription need to be performed to draw conclusions.
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Our megakaryocyte-specific approach to overexpression of FLI1 limits the scope
of this TF’s influence to mainly the megakaryocyte lineage, with minimal effects on the
erythroid cells due to the low activity of our murine Gp1ba promoter at the progenitor
stage as shown previously115. There is one previous report of in vitro overexpression of
FLI1 in PTSx patient cells82, yet the constitutive lentiviral expression strategy may be
driving already committed blood cells to transdifferentiate into megakaryocytes, not
necessarily correcting the PTSx megakaryocyte defects. With our PTSx-OE iPSC line,
we report rescue of PTSx cells during megakaryocyte maturation from HPCs (Figure
3.5); and restoration of megakaryocyte surface marker expression (Figure 3.7), ploidy
(Figure 3.8) and size (Table 3.3) to normal levels. As expected, erythroid differentiation
was slightly decreased while myeloid differentiation was unaffected by increased FLI1
(Figure 3.6). These data, along with the FLI1+/- iMeg data, support the conclusion that
FLI1 is the sole TF responsible for the PTSx and heterozygous dysmegakaryopoiesis.
However, since the in vitro platelet particles from all lines are of poor quality, it is still
unclear whether the platelets are negatively affected. This area was addressed via in
vivo studies.
On the other hand, overexpression of FLI1 in the normal WT iPSC line generated
megakaryocytes that exhibited improved characteristics. Both the WT-OE1 and WT-OE2
lines had iMegs that mature from the HPC stage more efficiently (Figure 3.5). They also
expressed higher levels of megakaryocyte surface markers and an increased ability to
retain CD42b (Figure 3.7), indicating they were less prone to in vitro injury and were
healthier cells overall. DNA analysis shows a trend towards higher level of
polyploidization (Figure 3.8), a sign of mature megakaryocytes171. Finally, TEM imaging
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of individual iMegs show more cells that have larger diameters compared to WT iMegs
(Table 3.3).
Because these are in vitro cultures with highly defined growing conditions and
media, the results may not be replicated in an in vivo setting. Further studies to evaluate
the in vivo thrombopoiesis of these gene-edited iMegs and the resulting in vivogenerated platelets (iPlts) from these iMegs could shed more light on the biology of FLI1.
We address this issue in the next chapter by infusing immunodeficient mice with iMegs
and studying in vivo thrombopoiesis over time. Functional characteristics of the resulting
iPlts were also evaluated.
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Tables

Target

Source
Monoclonal
mouse
Monoclonal
mouse
Monoclonal
mouse
Monoclonal
mouse
Monoclonal
mouse
Monoclonal
mouse

CD41a
CD41a
CD42a
CD42b
CD42b
CD235a
Annexin V

Bacteria
Monoclonal
mouse
Monoclonal
mouse
Polyclonal
rabbit
Monoclonal
mouse
Polyclonal
donkey

CD110
FLI1
PF4
TBP
IgG

Reactivity

Label

Company

Catalog
number

Human

APC

BD Biosciences

559777

Human

PE

BD Biosciences

555467

Human

BV421

BD Biosciences

565444

Human

APC

BD Biosciences

551061

Human

PE

BD Biosciences

555473

Human

APC

BD Biosciences

551336

Human

FITC

BD Biosciences

556420

Human

PE

BD Biosciences

562159

Human

BD Biosciences

554266

Western Blot

Human

PeproTech

500P05

Western Blot

Human

Abcam

ab818

Western Blot

Usage
Flow
cytometry
Flow
cytometry
Flow
cytometry
Flow
cytometry
Flow
cytometry
Flow
cytometry
Flow
cytometry
Flow
cytometry

Mouse

HRP

Abcam

ab6820

Western Blot

IgG

Polyclonal goat

Rabbit

HRP

Abcam

ab6721

Western Blot

CD41
MWReg30

Rat Fab2

Mouse

AF 647

BD Biosciences

553847

Intra-vital
injury

Table 3.1. List of antibodies used for iMeg analyses.
Description of antibodies used for flow cytometry and Western Blot analyses of HPCs,
iMegs and iPlts. Abbreviations: AF, Alexa Fluor; APC, Allophycocyanin; BV, Brilliant
Violet; FITC, fluorescein isothiocyanate; HRP, Horseradish Peroxidase; PE, Rphycoerythrin.
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Relative FLI1
mRNA Level of
iMegs (% ± SEM,
P value)

Relative FLI1
Protein Level of
iMegs (% ± SEM,
P value)

Name

Source

Genome Engineering
Technology Used

Control iPSC line
(WT)

Bone
marrow

Four-factor lentiviral
reprogram

100

100

FLI1
overexpression
(WT-OE1)

WT

AAVS1-targeted FLI1
transgene: 1 copy

431 ± 99
P = 0.020

686 ± 240
P = 0.088

FLI1
overexpression
(WT-OE2)

WT

AAVS1-targeted FLI1
transgene: 2 copies

494 ± 147
P = 0.006

895± 209
P = 0.024

FLI1
heterozygous
+/knockout (FLI1 )

WT

TALEN

125 ± 19
P = 0.369

62 ± 8
P = 0.013

Paris Trousseau
syndrome iPSC
line (PTSx)

Patient
fibroblasts

Four-factor lentiviral
reprogram

84 ± 15
P = 0.624

17 ± 10
P < 0.0001

PTSx FLI1
overexpression
(PTSx-OE)

PTSx

AAVS1-targeted FLI1
transgene: 1 copy

126 ± 12
P = 0.953

678 ± 301
P = 0.38

Table 3.2. iPSC lines and their relative iMeg mRNA and protein levels.
Summary of the iPSC lines used in this study. The various constructs were further
analyzed by direct sequence analysis and by relative FLI1 mRNA (n=4) and protein
levels (n=4), confirming genome-editing strategies. WT-OE1, WT-OE2, FLI1+/-, PTSx
and PTSx-OE lines were compared to WT by one-way ANOVA.

75

Cell line

Size (μm) ± SEM,
P value

Replicates (n)

WT

10.86 ± 0.34

11

WT-OE1
WT-OE2
FLI1

+/-

PTSx
PTSx-OE

11.17 ± 0.49
P = 0.985
16.27 ± 1.19
P < 0.0001
8.65 ± 0.60
P ≤ 0.05
9.88 ± 0.71
P = 0.410
10.83 ± 0.51
P > 0.999

9
11
13
8
9

Table 3.3. Size of iMegs measured on TEM imaging.
iMegs 5 days post differentiation from HPCs were prepped for TEM analysis and cell
diameter of 8-13 images measured using a JEOL 1010 electron microscope fitted with a
Hamamatsu digital camera and AMT Advantage image capture software. WT-OE1, WTOE2, FLI1+/-, PTSx and PTSx-OE lines were compared to WT by one-way ANOVA.
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Figures

Figure 3.1 Analysis of FLI1 mRNA and protein levels of iMegs.
iMegs were selected for CD41a and analyzed using qRT-PCR (Days 1-5) and Western
blot (Day 5). (A) Relative expression of FLI1 mRNA was performed using qRT-PCR
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compared to WT. Mean ± 1 SEM are shown of 4 separate experiments. P values were
calculated using one-way ANOVA. (B) Representative Western blot membrane image of
FLI1, PF4 and TPB (loading control). (C) Quantitative analysis of FLI1, relative
expression of FLI1 was compared to WT. Mean ± 1 SEM are shown for 4 separate
experiments. P values were calculated using one-way ANOVA.
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Figure 3.2. qRT-PCR analysis of iMegs for megakaryocyte-specific genes.
Same as Figure 3.1A. Mean ± 1 SEM are shown of 4 separate experiments. P values
were calculated using one-way ANOVA.
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Figure 3.3. Nearby enhancer activity may disinhibit ETS1 expression in FLI1
haploinsufficiency.
(A) Primary megakaryocyte ChIP-Seq data, depicted in purple, with area of interest ~100
kb downstream of the ETS1 gene body (yellow box; note that ETS1 is transcribed right
to left in this diagram). Overlying H3K4me1 and H3K27ac signals of several cell types
are depicted, which were created using the UCSC Genome Browser80: Cyan, HUVEC;
Red, GM12878; Orange, H1-hESC; Green, HSMM; Blue, K562; Lavender, NHEK; Pink,
NHLF. (B) A schematic model by which FLI1 binding to the region in the yellow box
could mediate ETS1 repression, and result in increased ETS1 transcription in FLI1
haploinsufficiency.
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Figure 3.4. iMeg MPL but not PF4 mRNA and protein levels correlate with FLI1
mRNA and protein levels.
iMegs were selected for CD41a and analyzed using qRT-PCR (Days 1-5) and Western
blot (Day 5). (A) Relative expression of MPL and PF4 mRNA was performed using qRTPCR compared to WT. Mean ± 1 SEM are shown of 4 separate experiments. P values
were calculated using one-way ANOVA. (B) Relative surface MPL expression analyzed
from 3 separate experiments using flow cytometry and one-way ANOVA. Western blot
analysis of PF4, similar to Figure 3.1 for FLI1. Relative expression was compared to WT.
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Mean ± 1 SEM are shown for 4 separate experiments. P values were calculated using
one-way ANOVA.
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Figure 3.5. Megacult colony numbers and iMeg differentiation in liquid culture
mirror FLI1 expression levels.
(A) HPCs were plated in a semi-solid Megacult colony system and analyzed at the end
of the assay for colony count per input HPC. Mean ± 1 SEM are shown along with the
number of independent experiments done. Significant P values done using one-way
ANOVA are shown. (B) HPCs were grown in liquid culture and analyzed at the end of
the assay for iMeg numbers. Relative expression to WT iPSC line is shown. Mean ± 1
SEM are shown along with the number of independent experiments done. P values were
calculated using one-way ANOVA.
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Figure 3.6. Erythroid colony numbers are changed by levels of FLI1 expression.
HPCs were plated in a semi-solid methocult culture system and colonies were scored 14
days later. Results are the mean ± 1 SEM of 3-6 independent experiments, with
numbers on the bar graph corresponding to number of replicates per line. P values were
determined using one-way ANOVA.

84

Figure 3.7. Percentage of annexinV-CD41+CD42a+CD42b+ iMegs and in vitroreleased platelets.
Day 5 iMegs and released platelet-like particles were analyzed for surface markers using
flow cytometry. (A) iMegs were negative for annexin V and positive for CD41a, CD42a,
and CD42b. (B) In vitro platelet-like particles positive for CD41a, negative for annexin V,
and positive for CD42b. Mean ± 1 SEM are shown with n=3-6 independent experiments
per arm. Significant P values were determined using one-way ANOVA.
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Figure 3.8. FACS analysis of iMeg DNA content.
Ploidy was determined via FACS after iMeg DNA was stained. There are no significant
differences among the groups after 1-way ANOVA analysis, but the trend was similar to
surface marker analyses where PTSx and FLI1+/- iMegs had less mature iMegs, shown
here through less cells with 4N and higher ploidy, and WT-OE1 and WT-OE2 having
more high ploidy cells. Results are the mean ± SEM of 3-4 independent experiments.
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Figure 3.9. iMeg ultrastructures and pro-platelet protrusions
Representative TEM images of iMegs were analyzed at 10,000X and 40,000X for
relative size and presence of pro-platelet protrusions (*), granules (black arrows) and
open canalicular systems (white arrows) via TEM imaging. Nuclei are denoted with “N”
and mitochondria with “M”. Micrographs taken using a JEOL 1010 electron microscope
fitted with a Hamamatsu digital camera and AMT Advantage image capture software
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CHAPTER 4 – In vivo analysis of infused FLI1-modified iPSC-derived
megakaryocyte thrombopoiesis and released platelets
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Abstract
We showed that iPSC-derived megakaryocytes (iMeg) are not only an unlimited
source of cells, but also a viable one for studying in vitro questions of FLI1-related
megakaryopoiesis. Having established that PTSx and FLI1+/- iMegs exhibit similar in vitro
characteristics as primary megakaryocytes, such as small cell size and reduced
numbers, we now infused immunodeficient mice to test in vivo properties of iMeg
thrombopoiesis and released platelet function. We found that platelets released in vivo
from infusion of these iMegs had fewer platelets released per iMeg, and the platelets
that were released had poor half-lives and functionality. Finally, we found increased in
vivo yield, half-life and functionality of released platelets from iMegs that overexpressed
FLI1. Together, these in vivo data illustrate a novel approach to studying a critical
megakaryocyte-specific TF that is hard to replicate in animal models and may be more
clinically relevant.
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Introduction
While the studies of PTSx and FLI1 mutations describe clinical hematologic data
and some in vitro analyses, none have shown a detailed examination of platelet biology
beyond transmission electron microscopy images of ultrastructures. To fully understand
the platelet defects attributable to FLI1 deficiency, comprehensive investigations need to
be performed comparing affected platelets to those that are derived from the same
genetic background aside from the expression of FLI1. I address in this Chapter platelet
biology from infused iPSC-derived megakaryocytes with different expression levels,
confirming the utility of this approach to studies of thrombopoiesis and released platelet
biology beginning with iPSCs.
In Chapters 2 and 3, I outlined the need for a better model to study
megakaryopoiesis associated with the FLI1 TF, detailed the creation of isogenic iPSC
lines from the same genetic background that had increased or decreased FLI1
expression levels, and presented in vitro analyses of the resulting FLI1-modified iMegs
that recapitulated the PTSx and FLI1 mutation patient defects and provided a
megakaryopoiesis “correction” or improvement strategy with overexpression lines. This
Chapter highlights a novel approach at studying in vivo thrombopoiesis of gene-edited
iMegs and in vivo-released platelet biology.

Methods
Characterization of in vivo-generated platelets from infused iMegs
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Non-obese diabetic (NOD)/SCID/interferon receptor 2g-deficient (NSG) mice
(Jackson Laboratory, Bar Harbor, ME) are severely immunodeficient and lack mature T
cells, B cells, functional NK cells, and are also deficient in cytokine signaling172. We used
this mouse strain to study in vivo thrombopoiesis of our human iMegs. Male NSG mice
were infused at 8-12 weeks of age via tail vein with 1-2 X 107 iMegs suspended in 200 µl
of PBS and 1% BSA. Isolated human platelets from healthy donors were similarly
infused as a positive control. Retro-orbital blood collection was performed at various
intervals post-infusion, and the human platelets and platelet-like particles from iMegs
(iPlt) were stained with anti-human CD41a antibody to distinguish them from the native
murine platelets170. Loss of the glycocalicin, an indicator of megakaryocyte injury173, was
measured using anti-human CD42a versus anti-human CD42b antibodies in addition to
annexin V staining (Antibodies used for experiments in this Chapter are described in
Table 3.1).

Functional analysis of iPlts via measurement of response to thrombin activation
Baseline human platelet activation and responsiveness to agonist in isolated
murine blood were assessed by surface P-selectin levels in the absence and presence
of thrombin. NSG mice were infused as above and ~1 ml of whole blood was collected 4
hours later from the inferior vena cava. Washed platelets were isolated and resuspended
into Tyrode’s buffer at pH 7.2, as described previously174. Platelet activation with 1 U/ml
thrombin (Sigma-Aldrich) was performed for 30 minutes at 37°C then analyzed by flow
cytometry.
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Functional analysis of iPlts via measurement of incorporation into active thrombi
Human platelet function was assessed using the intra-vital arteriole laser injury
model as described175. iMegs were pre-labeled with 2 mM calcein AM (Invitrogen) for 30
minutes at 37°C, washed once with PBS, then resuspended in 200 µl PBS and 1% BSA
before infusion via the tail vein of male NSG mice. To label mouse platelets, Alexa Fluor
647-labeled rat monoclonal anti-mouse CD41 Fab fragments (BD) were injected
intravenously shortly before injury. Laser-induced injuries of cremaster arterioles were
performed 4 hours after iMeg infusion. Human platelet incorporation was recorded by
confocal microscopy and compared to the concurrent circulating percent of human
platelets in mouse blood176.

Statistical analysis
Statistical analysis was performed using one-way ANOVA and data was reported
as mean ± 1 standard error of the mean (SEM) using the GraphPad Prism software
version 6.00 for Mac (GraphPad Software). Differences were considered significant
when the P value was less than 0.05.

Study approval
Animal studies and human tissue sampling were done in accordance with
CHOP’s Institutional Animal Care and Use Committee and Institutional Review Board,
respectively.
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Results
In vivo-released iPlts from infused iMegs in NSG mice
Since in vitro-generated platelet-like particles were only ~50% platelets with most
of these platelets being injured (Figure 4.1), platelet analyses in our studies focus on in
vivo-released platelet biology from iMegs. We have previously shown that infused
human megakaryocytes, including iMegs, into immunodeficient NSG mice release iPlts
intrapulmonarily beginning almost immediately170. These platelets have comparable sizedistribution, half-life and functionality as donor-derived platelets, in contrast to in vitroreleased platelet-like particles170. iMegs of the various FLI1 lineages were infused into
NSG mice, and the number and functionality of the released iPlts measured. Released
iPlts over 24 hours were calculated as a percentage of human CD42b+ that, on forward
scatter analysis, had a size range similar to that of infused human donor platelets. This
value was normalized to the number of CD42b+ iMegs infused (Figure 4.1A) and
separately to the number of HPCs needed to generate those iMegs (Figure 4.1B). Area
under the curve (AUC) was calculated from these values. AUC of FLI1-low (PTSx and
FLI1+/-) iPlts released was significantly less than WT per iMeg and per HPC, while PTSxOE released the same number of platelets per iMeg and per HPC as WT (Figures 4.1C
and 4.1D, respectively). WT-OE1 and WT-OE2 released the same number of platelets
per iMeg (Figure 4.1C), but an ~50% increase per HPC (Figure 4.1D) consistent with the
higher yield of iMegs per HPC seen in these two lines in Figure 3.5B.
Calculated WT iPlt in vivo half-life was ~4 hours, comparable to our previously
published value170 (Figure 4.2). For the PTSx and FLI1+/- lines, iPlt half-lives were
decreased to ~1 and ~2 hours compared to WT, respectively. PTSx-OE iPlts had a half95

life of ~3 hours, comparable to WT-released platelets, while WT-OE1 and WT-OE2 iPlt
half-lives were increased to ~7 and ~11 hours, respectively (Figure 4.2).

Released iPlt function
PTSx platelets have been reported to be dysfunctional as well as reduced in
number78,79,151. We asked what the effect was of FLI1 expression levels on platelet
functionality in the released iPlts from the various FLI1-iMeg lines. Whole blood was
drawn from NSG mice 4 hours after iMegs were infused and washed platelets isolated.
These platelets were analyzed via flow cytometry for surface P-selectin, a marker of
platelet alpha-granule degranulation as an indicator of platelet activation177, pre- and
post-activation with thrombin (Figure 4.3). Pre-activation levels of P-selectin on CD41+
and CD41+CD42b+ iPlts were comparable across all lines, indicating that all iPlts were
equally quiescent (Figures 4.3A and 4.3B, respectively). Post thrombin activation, both
FLI1-low CD41+ iPlt lines were hyporesponsive compared with WT iPlts, likely because a
significant number of these iPlts were pre-injured as megakaryocytes (Figure 3.7). The
FLI1-low CD41+CD42b+ iPlts showed normal responsiveness indicating that uninjured
FLI1-low iPlts retained responsiveness. The overexpressing lines all showed increased
responsiveness to thrombin relative to WT iPlts.
We also assessed iPlt function in vivo by visualizing human platelet incorporation
into laser-induced cremaster arteriolar injuries as previously described175. We compared
iPlts from 3 lines: WT, WT-OE1 and FLI1+/- (Figure 4.4). Data were consistent with the
thrombin stimulation studies: active platelet incorporation into thrombi of WT-OE1 iPlts
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had comparable active incorporation as WT, while the incorporation FLI1+/- iPlts was
decreased in comparison.

Discussion
In the previous Chapter, I presented flow cytometry data of in vitro-generated
platelet particles, showing that the majority of CD41+ platelet-like particles were already
activated or injured (Figure 3.7B). This phenomenon has been reported before by our
group170, and suggests the platelets present in the tissue culture dish at the end of
megakaryocyte differentiation are old and functionally limited. We have previously shown
that infused human megakaryocytes, including iMegs, into immunodeficient NSG mice
release iPlts intrapulmonarily beginning almost immediately170 similar to that seen
endogenously in mice where ~50% of platelets are released from megakaryocytes
entrapped in the lungs178. Therefore, we instead used an alternative strategy by infusing
iMegs into NSG mice as an in vivo method of generating young platelets176. We did not
treat these mice with clodronate liposomes that deplete macrophages from the mouse
circulation, so that the mice were sufficiently immunocompetent to remove injured and
pre-activated platelets that accompanied the infused iMegs. This allowed us to assess
characteristics of only quiescent platelets that were not immediately cleared by mouse
macrophages170. Infusing iMegs into NSG mice and tracking iPlt generation over time,
we saw a biphasic iPlt generation curve (Figure 4.1). A peak occurred between the 5and 30-minute time points that indicate the platelet-like particles that had already been
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released in culture. Between 4- and 6-hours post infusion, CD42b+ iPlts were released
from entrapped iMegs in the pulmonary beds of the recipient mice.
Comparatively, both PTSx and FLI1+/- iPlt generation are decreased per iMeg,
and the PTSx-OE generation curve returned to normal. These calculations have already
been normalized to account for only the uninjured CD42b+ iMegs, indicating that while
there may be healthy in vitro FLI1-deficient iMegs, they underwent diminished
thrombopoiesis in an in vivo setting either calculated per iMeg or initial HPC. The WTOE1 and WT-OE2 lines released as many iPlts per iMeg as the parent WT iMegs.
However, considering the higher number of iMegs differentiated from HPCs (Figure 3.5),
an ~50% increase in iPlt release was observed per HPC. The FLI1-low iPlts had
shortened half-lives compared to WT iPlts, perhaps related to a higher level of baseline
injury or decreased surface levels of important receptors system (Figure 3.7A) or to
some additional pathway that affects platelet half-life such as the described Bcl-xL
programmed cell death pathway179. The shortened half-life could also be due to
increased platelet desialylation, prompting removal via the hepatic Ashwell-Morell
receptor180,181. Conversely, the WT-OE1 and WT-OE2 iPlts appeared to survive longer
(Figure 4.2), approaching the half-life we described for donor-derived infused
platelets170. Whether this is related to decreased in vitro injury, increased surface
receptor levels shown in Figure 3.7A, altered cell death pathways or decreased platelet
desialylation needs further study.
We confirmed iPlt functional robustness by performing an ex vivo-activation
study. Whole blood containing in vivo-released iPlts was isolated at 4 hours, which
corresponds to the time point where circulating levels of the CD42b+ iPlts was highest
(Figure 4.1). These iPlts with different FLI1 levels were indistinguishably quiescent
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before activation (Figure 4.3). Once activated with thrombin, surface P-selectin levels did
not increase as much on total CD41+ particles derived from infused PTSx and FLI1+/iMegs (Figure 4.3A); however, the few CD42b+ iPlts present were normal (Figure 4.3B)
suggesting that injury of FLI1-low iPlts is an important component of their decreased
functionality. In comparison, all iPlts generated from FLI1 overexpressing line were more
responsive relative to WT iPlts and coincidentally were derived from iMegs with less
injury as indicated by loss of surface CD42b (Figure 3.7A). Whether the two
observations are related will need to be tested. Finally, we compared the ability of these
iPlts to be incorporated into growing mouse thrombi, using WT, WT-OE1 and FLI1+/lines (Figure 4.4). These studies support that released FLI1-low iPlts are qualitatively
defective and that overexpressing FLI1 did not decrease iPlt functionality.
By studying in vivo thrombopoiesis of iMegs coming from various FLI1-modified
iPSC lines, we present novel insights into FLI1 influence on this cellular process and
shed light on the pathogenesis of PTSx and other FLI1-deficient platelet defects. We
confirmed that the defect occurred at all stages of megakaryocyte and platelet
maturation. Furthermore, injury at one stage can affect biology downstream. Starting at
the HPC differentiation into iMeg stage, FLI1-low lines already exhibited a defect. Then,
the defect extended into the stage of in vitro iMegs releasing in vivo iPlts. Additionally,
these iPlts were functionally inferior to normal iPlts, not being able to respond to
thrombin or participate in clotting as well as normal cells. On the other hand, FLI1
overexpression driven by the Gp1ba promoter was not deleterious. In fact, this strategy
may enhance iMeg yield per HPC while limiting in vitro injury to developing
megakaryocytes. FLI1 overexpression was also not deleterious to thrombopoiesis, with
WT-OE iMegs releasing iPlts that were actually as good or better than WT iPlts in half99

life and agonist responsiveness. These data may have implications for future clinical
applications.
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Figures

Figure 4.1. In vivo iPlt generation is decreased for FLI1-low and increased for FLI1high lines.
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In (A) and (B), NSG mice were infused with iMegs, and percent of human platelets were
determined at various time points up to 24 hours. Mean ± 1 SEM are shown with 4-7
independent experiments per arm. (A) Left: Data analyzed per infused iMegs generated
from isogenic genome-edited iPSC lines. Right: Data analyzed per infused iMegs WT
iPSCs and the two PTSx lines. (B) Same as in (A), but analyzed per initial HPCs from
which the iMegs were prepared. (C and D) AUC calculations for iPlt generation either
from iMegs (C) or from HPCs (D). Mean ± 1 SEM are shown with number of
independent experiments per arm shown in each bar. Significant P values were
determined using one-way ANOVA.
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Figure 4.2. iPlt half-life is decreased for FLI1-low and increased for FLI1-high lines.
Percent of peak iPlt generation up to 24 hours after iMeg infusion into NSG mice (n=4-7
independent experiments, same as Figures 4.1A and 4.1D). Half-life is determined by
the time at which there is 50% of iPlts compared to peak iPlt numbers.
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Figure 4.3. iPlt response to activation is decreased for FLI1-low and increased for
FLI1-high lines.
(A) CD41+ and (B) CD41+CD42b+ iPlt mean fluorescence intensity (MFI) of surface Pselectin before and after thrombin stimulation of iPlts generated at 4 hours after iMeg
infusion. Mean ± 1 SEM are shown with n=6 independent experiments per arm.
Significance was determined by one-way ANOVA.
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Figure 4.4. iPlt incorporation into thrombi is decreased for FLI1-low and increased
for FLI1-high lines.
Intra-vital cremaster injuries were induced at 4 hours after iMeg infusion in NSG mice
and fluorescent images were recorded. The numbers reported are of human particles
incorporated into a growing thrombus normalized to circulating percentage of CD42b+
iMegs in the mouse blood at the time. Shown are the individual data point and mean ± 1
SEM of experiments from four individual mice with up to six injuries per mouse.
Significance was determined by one-way ANOVA.
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CHAPTER 5 – Discussion and future directions
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Addressing the challenges of studying FLI1 in megakaryopoiesis
Murine models that have been established to study FLI1 and its relation to
megakaryopoiesis have provided important insights into its overall biology, like the
essentiality of FLI1 for vasculargenesis182 and megakaryopoiesis53,183, yet the details of
its regulation of megakaryopoiesis differs from that in humans. Murine models of Fli1gene targeting did not replicate the PTSx syndrome52 or the biology in the growing
number

of

individuals

recognized

with

FLI1

mutations

and

inherited

thrombocytopenias84. We, therefore, turned to the relatively new iPSC technology to
address key clinical questions related to the role of FLI1 in megakaryopoiesis,
thrombopoiesis and platelet biology. While in vitro-generated iMegs do not fully replicate
the biology of CD34-derived or primary megakaryocytes170, they offer the advantage of
unlimited access to genetically modified iMegs that can be studied in parallel with control
iPSC lines in which gene editing has been performed, and we have developed strategies
in our group to specifically study questions related to megakaryopoiesis, thrombopoiesis
and platelet biology.

iPSCs and gene editing
Disease modeling for rare and multigenic disorders can be a challenge, but iPSC
technology has made it possible to generate a stable cell line from diseased patients that
accurately reiterate the disease phenotype in vitro. Using this to our advantage, we
created a PTSx iPSC line and found that the megakaryocyte and platelet defects are
indeed replicated in our hematopoietic differentiation protocols. We believe the cardiac,
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kidney, and other organ defects associated with these patients could also be modeled
with the same iPSCs.
Another advantage of using iPSCs is the ability to use recently developed gene
editing technologies to modify specific genes from the same cell line and compare
differences in cells coming from the same genetic background. Consequently, we used
ZFN technology to overexpress FLI1 in the hematopoietic/megakaryocyte lineages and
TALEN technology to heterozygously disrupt the FLI1 gene. The end-product cell lines
could be compared to the parental cell line with the presumption that they only differ by
the genetic alteration induced. Moreover, gene targeting allows one to replicate mutant
iPSCs without the need to have available patients.
The FLI1-modified iMeg studies presented here provide novel insights into the
role of FLI1 during megakaryopoiesis, thrombopoiesis and platelet functionality. In vivoreleased iPlts from infused iMegs also allowed us additional characterization of platelets
that are comparable to donor-derived platelets, which was not possible by studies of in
vitro-released platelet-like particles, of which only roughly half are CD41+ and of those,
most are negative for CD42b and bind annexin V, indicating that they are injured and/or
apoptotic184.

Correction of the PTSx megakaryocyte and platelet phenotypes
We demonstrate that PTSx iMegs and iPlts replicated many of the known defects
seen in this syndrome, beginning with a decrease in the number of iMegs derived per
HPC and also decreased expression of megakaryocyte-specific markers. Moreover, we
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observed a redirection of HPCs towards the erythroid lineage, limiting the number of
resulting iMegs in vitro. Furthermore, these studies show a clear defect in the ability to
shed iPlts relative to normal iMegs in vivo, with FLI1-low iPlts having decreased
responsiveness to the thrombin agonist and a decreased ability to be incorporated into a
growing thrombus. Since PTSx is part of a larger syndrome associated with significant
chromosomal deletions, it was not clear that all the defined defects were related to the
deletion of FLI176,81. The following lines of evidence presented support that the
megakaryocyte and platelet defects are predominantly or entirely due to the FLI1
deficiency: (1) Megakaryocyte-specific overexpression of FLI1 in PTSx iMegs largely
corrected the defects in megakaryopoiesis, thrombopoiesis and platelet biology even
with a large 15.3 Mbp deletion on chromosome 11q. (2) Similar findings were observed
for both the PTSx and FLI1+/- iMegs. (3) The TF ETS1, which is physically linked to
FLI180, is always deleted in PTSx76,79, and important in megakaryopoiesis20; appears to
be inversely regulated by FLI1. In the PTSx and FLI1+/- iMegs, the level of ETS1 is at
least normal. There is no ETS1 TF deficiency in megakaryocytes from patients with
PTSx.

FLI1 monoallelic expression
Primary megakaryocytes isolated from two patients with PTSx had been
previously studied and the results were consistent with these iMeg findings. However,
that study also raised the possibility that FLI1 expression undergoes monoallelic
expression based on very limited analysis of the final megakaryocytes seen82. This
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concept that FLI1 undergoes allelic exclusion, resulting in half of the megakaryocytes
coming from the missing FLI1 allele being affected and the other half normal, has since
been echoed by others83. We examined whether either PTSx or FLI1+/- HPCs
transitioning to iMegs gave rise to two distinct megakaryocytic populations consistent
with monoallelic expression, but did not observe two populations. In a collagen-based
culture system, PTSx HPCs gave rise to virtually no large colonies, not just half as many
as allelic exclusion would predict, and this was also seen with the FLI1+/- line (Figure
3.5A). The vast majority of PTSx iMeg-derived iPlts also had a markedly shortened halflife after infusion of the iMegs into NSG mice (Figure 4.1). Thus, if monoallelic
expression of FLI1 had occurred, then the lower yield of iMegs per HPC, the lower yield
of iPlts per iMeg and the poor half-life of the FLI1-deficient iPlts compared to WT iPlts
would mean that most of the circulating iPlts in a PTSx patient would be from the normal
allele, and dysfunctional macrothrombocytes would be a considerable minority in
patients rather than dominating the patients’ platelet presentation52,75,79,151.

Improved megakaryopoiesis and platelet function by FLI1 overexpression
A prior study using megakaryocytes derived from the murine stem cell line G1ME
suggested that continuous overexpression of TFs involved in megakaryopoiesis, such as
GATA1, may harm overall megakaryocyte formation, thrombopoiesis and platelet
biology185. We were, therefore, surprised to see that WT-OE1 and WT-OE2 lines
underwent normal to enhanced megakaryopoiesis, lost less CD42b from these iMegs
than WT iMegs in vitro and exhibited an extended iPlt half-life with normal platelet
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functionality. The Gp1ba promoter is known to drive expression of a reporter gene at low
levels

during

hematopoiesis

and

then

at

a

much

higher

level

during

megakaryopoiesis115. Perhaps this temporal expression profile sufficiently coincides with
that of FLI1 during normal human megakaryopoiesis. Alternatively, FLI1 overexpression
during megakaryopoiesis may have less deleterious effects on megakaryocyte
differentiation than continuous GATA1 overexpression or overexpression of TFs during
murine megakaryopoiesis may be more deleterious than in human megakaryopoiesis.
Indeed, human megakaryocyte progenitors constitutively overexpressing GATA1, FLI1
and TAL1 differentiated into megakaryocytes that appeared at least partially
functional186, although the in vivo biology of the released platelets was not rigorously
tested, as the recipient immunodeficient mice were pretreated with clodronate
liposomes, a technique that has previously been shown necessary to prolong the half-life
of injured platelets170. Also whether in that paper, FLI1 overexpression compensated for
GATA1 overexpression, which allowed for normal megakaryopoiesis. This certainly was
not addressed.

FLI1 may act as a suppressor of ETS1 transcription
Our findings of the ETS1 transcript levels of the various FLI1-modified lines were
quite unexpected. We had anticipated the PTSx and PTSx-OE lines to be ETS1
deficient, since they lack one copy of ETS1 due to the 11qter deletion. The transcript
levels, however, were increased up to 4-fold in the PTSx line compared WT levels, with
the PTSx-OE showing a slight increase then decrease to the level of the other FLI1
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overexpressing lines. The transcript level increase of the PTSx line was also reflected in
the FLI1+/- iMegs, which start their megakaryocyte differentiation at normal ETS1 levels
on Day 1, but then experience a sustained increase throughout the rest of differentiation.
Published ChIP-Seq data revealed a FLI1-binding site near ETS1
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that localized to

markers of active enhancers157-159. These mRNA expression patterns, along with
chromatin state analysis, could indicate a role of FLI1 in regulating ETS1 transcription.

Clinical implications
Our studies contribute to the basic understanding of the biology of FLI1 as it
pertains to the megakaryocyte blood lineage, but they also have clinical implications. We
show evidence with our PTSx-OE iPSC line that tissue-targeted gene editing can be a
viable treatment for FLI1-deficient patients specifically, and perhaps other monogenic
disorders in general. Our FLI1+/- iPSC line has similar megakaryocytic and platelet
features as the patient cells, indicating that this line may be a genetically clean model
without the other missing genes in PTSx for discovery studies of compounds that may
improve FLI1 TF activity as detailed below. The WT-OE lines, with their ability to make
better iMegs and iPlts could be developed into an in vitro iPSC source of cells for
transfusion products. This feature may be incorporated into a final iPSC line designed for
large-scale iPlt preparation to enhance uninjured iMeg yield per initial HPC with no
deleterious effects on iPlt functionality. The end product would perhaps have a
prolonged circulatory half-life as well, as detailed above.
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Gene therapy
With the advent of technologies that allow fast and efficient sequencing of
genomic DNA, we can now characterize both inherited and de novo genetic mutations
that are the cause of life-threatening or debilitating symptoms. Strides have been made
in the past ~20 years in the pursuit for corrections to genetic disorders. Gene therapy is
no longer a dream but a reality, with over 2000 gene therapy clinical trials that are
approved, ongoing or completed for cancer, cardiovascular, monogenic and other
diseases187. We believe our studies provide an impetus for pursuing gene therapy for
FLI1-deficient patients.
We show evidence that iPSCs created from a PTSx patient make poor
megakaryocytes and platelets with quantitative and qualitative defects, but can undergo
normal megakaryopoiesis and thrombopoiesis and have functional platelets after a
single copy FLI1 cDNA driven by the GP1ba promoter was inserted into the genome at
the AAVS1 safe harbor locus. We observed that all parameters tested showed a rescued
phenotype: number of healthy, uninjured iMegs per HPC, number of iPlts released in
vivo, and half-life and function of released iPlts. Based on these results, we propose
potential avenues for gene therapy for correction of the platelet defects associated with
FLI1 deficiency.
Unfortunately, PTSx is part of JSx, a larger disease that is more often than not
life-threatening to afflicted patients due to the large hemizygous deletions involving many
genes. While we were able to abrogate the megakaryocyte and platelet pathology in our
PTSx iPSC line, these patients are frequently in need of more pressing treatments for
their life-threatening complications present to other targeted organs. Because of this, it is
probably highly unlikely PTSx patients will be suitable candidates to undergo a FLI1113

centric gene therapy treatment to fix their platelets. However, recent evidence suggests
that a significant portion of patients with inherited platelet disorders are heterozygous for
inactivating mutations on FLI184,85. By targeting these specific mutations and replacing
them with the correct coding sequence, the bleeding diathesis of these patient will more
than likely permanently resolve due to better transcriptional regulation of megakaryocyte
and platelet genes by the corrected FLI1. Alternatively, gene therapy with the strategy
described here, involving a vector driving FLI1 expression using the Gp1ba promoter
might be useful in correcting the bleeding diathesis in such patients, with little concern of
FLI1 over correction. In these patients, the drive for gene therapy intervention will
depend on the degree of thrombocytopenia and bleeding diathesis seen and its impact
on an individual.

Drug screening
A potential application for the FLI1+/- iPSC line may lie in drug discovery. Since
this line has the single FLI1 genetic mutation, it would be a useful tool to screen for
compounds that specifically help to increase FLI1 TF expression level or enhance its
activity. With an increasing number of inherited platelet disorders being identified with
FLI1 mutations, perhaps the discovery of a drug that specifically targets FLI1 activity will
abrogate the platelet defects. Such an approach by using a PKCd agonist that enhances
FLI1 phosphorylation and activity has already been described to drive cells lines towards
megakaryocytes and suppresses leukemogenesis due to heterozygous acquired loss of
FLI1188. We believe that our FLI1-low iPSC lines may be useful to confirm these findings
and/or screen for additional drugs that may be clinically useful, perhaps by beginning
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with a library of drugs already approved for clinical application (Selleckchem, Houston,
TX).

Developing iMegs for in vivo platelet release
Many groups have pursued an in vitro-derived platelet product to replace the
reliance on donor platelets that have many issues relating to storage, immunity and
contamination189. Some have proposed an in vitro source of platelets that has the
properties of being both renewal and reliable for patients who need near constant
transfusions for their disorder190-192. None have succeeded thus far to provide a
comparable or better product than donor-derived platelets. We show in our WT-OE
iMegs and iPlts a viable solution for an enhanced source of in vitro-grown
megakaryocytes derived from iPSC-derived HPCs that also release a longer-lived, less
injured and functional in vivo-released iPlt product. This feature can be incorporated in a
final “platelet” iPSC line for large-scale platelet production with other features that can
include being less immunogenic with loss of surface HLA markers193 or delivering a
protein of interest stored in its a-granules194,

Conclusions
In summary, to gain a better understand of the role of FLI1 in megakaryocyte and
platelet biology, we have studied iMegs derived from iPSCs generated from a patient
with PTSx as well as those of a WT iPSC line that has been FLI1 heterozygouslydisrupted. We have also genome-modified the WT and PTSx iPSC lines to overexpress
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FLI1 in a megakaryocyte-specific fashion. With the two FLI1-deficient lines, we confirm
the central role of heterozygous FLI1 loss in the megakaryocyte and platelet defects
observed in PTSx and in patients with FLI1 heterozygous mutations, as well as detail
their qualitative and quantitative defects. We also show that ETS1 deficiency does not
contribute to the PTSx platelet phenotype and that monoallelic expression of FLI1 does
not occur. Using iPSC lines that overexpress FLI1 in HPCs and in iMegs, we did not find
any deleterious effects. FLI1 overexpression instead enhanced megakaryopoiesis,
thrombopoiesis and platelet functionality. Whether overexpression of FLI1 in in vitrogrown megakaryocytes can improve yield and functionality of platelets for clinical usage
remains to be tested.
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